Introduction {#s1}
============

In mammals, embryonic and postnatal development depends on nutrition from placentation and lactation, respectively ([@bib7]).Before birth, hepatic energy metabolism relies mainly on glucose catabolism. Metabolic fluxes change abruptly at birth when milk, which has a higher lipid but relatively lower glucose content, becomes the exclusive nutrient ([@bib23]). At the first few hours after birth, liver expresses the rate-limiting enzymes responsible for extracting energy from milk ([@bib36]; [@bib29]). However, whether lipid catabolism at birth is developmentally programmed or an adaptive response requiring an external stimulus remains unknown. Failure to adapt to this catabolic switch results in life-threatening errors of metabolism, with serious energy imbalances that are recapitulated in mouse models of neonatal liver steatosis ([@bib31]; [@bib10]).

Peroxisome proliferator-activated receptor α (PPARα) is a key transcriptional regulator of lipid metabolism owing to its activation by a lipid surge to induce lipid catabolism ([@bib16]; [@bib41], [@bib40]). However,the role of PPARα in the perinatal liver is not fully understood. Certain PPARα target genes (e.g., acyl-CoA oxidase 1 \[*Acox1*\]) are highly expressed in fetal liver at the end of gestation, whereas the expression of others (e.g., fibroblast growth factor 21 \[*Fgf21*\]) strictly depends on postnatal milk uptake ([@bib28]; [@bib64]). Based on these contrasting observations, we hypothesized the presence of a PPARα-triggering program before birth that does not require milk suckling for activation. Given that fetal liver metabolism mostly relies on glycolysis rather than lipid oxidation, we postulated that the liver phenotype of PPARα-deficient fetuses may not be obvious due to the absence of a lipid-rich diet challenge.

By measuring gene expression in prenatal and postnatal livers, we show that PPARα activation has already occurred a few days before birth, and that glucocorticoid receptor (GR)-mediated control of PPARα in late gestation prepares its physiological role in the pups for harnessing milk lipids immediately after birth. However, before birth we could barely detect the expression of certain PPARα target genes such as *Fgf21*, which is exclusively involved in adaptive metabolism. Therefore, we explored the mechanistic basis for the temporal regulation of PPARα target genes. We found that certain PPARα target genes, including *Fgf21* and *Angptl4* (Angiopoietin-like 4), are epigenetically controlled by histone deacetylase 3 (HDAC3) and de-repressed in response to β-hydroxybutyrate, a by-product of fatty acid oxidation (FAO). Taken together, our data provide the evidence of a major role of glucocorticoid signaling in direct hepatic regulation of PPARα and indirect HDAC3-mediated regulation of FGF21, which controls important metabolic and thermogenic events in the early days of life ([@bib28]).

Results {#s2}
=======

GR controls PPARα expression in the late fetus {#s2-1}
----------------------------------------------

Stress at labor is associated with high glucocorticoid signaling ([@bib5]). We previously reported that glucocorticoids stimulate PPARα expression in the adult liver, but the mechanism was not elucidated ([@bib38]). Interestingly, the mRNA expression of GR (*Nr3c1*) in the fetal liver is the highest just before birth ([@bib53]).Because GR plays a role in the preparation for birth ([@bib12]), we further tested GR implication in the regulation of fetal PPARα expression. We confirmed that *Nr3c1* mRNA levels in the fetal liver peak at embryonic day E19.5, similar to *Ppara* mRNA expression ([Figure 1A,B](#fig1){ref-type="fig"}). Notably, *Ppara* mRNA levels were low in the liver at E13 and E15, but markedly increased at E17, peaking just before birth at E19.5 ([Figure 1B](#fig1){ref-type="fig"}). This observation coincides with a maximal RNA polymerase 2 (Pol2) recruitment to the PPARα transcriptional start site (TSS) ([Figure 1C](#fig1){ref-type="fig"}) and enhanced nuclear accumulation of PPARα protein similar to the levels in the postnatal pups (Figure 5A). Interestingly, we also observed a significant reduction in the expression of *Nr3c1* in *Ppara^-/-^* livers during development when compared with *Ppara^+/+^*controls ([Figure 1A](#fig1){ref-type="fig"}), suggesting that PPARα may also reciprocally regulate *Nr3c1* expression. To investigate the regulation of PPARα expression by GR, we treated E15 fetal liver explants, when *Ppara* expression is relatively low, with GR agonist dexamethasone, which induced *Ppara* mRNA expression in a dose-dependent manner ([Figure 1D](#fig1){ref-type="fig"}). We also examined the expression of *Ppara* in GR-null fetuses at E17 ([Figure 1E](#fig1){ref-type="fig"}), when *Ppara* mRNA levels just begin to increase in the wild-type fetal liver ([Figure 1B](#fig1){ref-type="fig"}). GR exerted a gene dosage effect on the expression of both *Ppara* and its target genes, including *Cpt1a, Hadha, Hadhb*, and *Cyp4a14* ([Figure 1E,F](#fig1){ref-type="fig"}).10.7554/eLife.11853.003Figure 1.GR directly controls fetal PPARα expression.(**A**, **B**) Ontogenic expression of *Nr3c1* (**A**) and *Ppara* (**B**) mRNA in the developing mouse liver. \*p\<0.05, \*\*p\<0.01 vs. E13 samples; ^\#^p\<0.05, ^\#\#^p\<0.01 vs. WT counterparts. (**C**) Enrichment of the DNA fragments containing the PPARα TSS using anti-Pol2 antibodies or pre-immune control IgG with or without PPARα agonist (WY-14643) treatment in pregnant dams. \*\*p\<0.01, \*\*\*p\<0.001 vs. respective WT counterparts without WY-14643 treatment. (**D**) *Ppara* mRNA levels in the E15 *Ppara*^+/+^ liver explants with or without dexamethasone (Dex) treatment for 24 hr. Dex concentrations of 0.1 μM, 1 μM, and 10 μM were used. The vehicle control group was treated with 0.1% ethanol. \*p\<0.05 vs. vehicle control. (**E**,**F**) mRNA expression of PPARα and its target genes in the fetal livers of GR models at E17. *\**p\<0.05, *\*\** p\<0.01, *\*\*\**p\<0.001 vs. *Nr3c1^+/+^* liver. (**G**) Alignment of the GRE consensus sequence with the three putative GRE sequences located upstream of the PPARα promoter. (**H**) Enrichment of the DNA fragment containing the three putative GRE found within the PPARα promoter at regions spanning −1007 to −993, −2080 to −2066, and −2953 to −2939 in fetal liver at E17 using anti-GR antibody or pre-immune control IgG. Enrichment levels were expressed as the percentage input. GR-targeting siRNA was used to knockdown *Nr3c1* expression and to determine the specificity of GR binding to this putative GRE. *\**p\<0.05 vs. non-targeting siRNA treatment group. (**I**) Enrichment of GRE spanning -1007 to −993 of the PPARα promoter in *Ppara*^+/+^ liver during development. \*p\<0.05, \*\*p\<0.01 vs. E13 samples. Data are presented as mean ± SEM; n = 4--6. Statistical analyses were performed using two-tailed Mann-Whitney tests.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.003](10.7554/eLife.11853.003)

Next, we addressed the mechanisms involved in priming the high expression and activity of PPARα just before birth. We identified three putative GR response elements (GRE) in the promoter/regulatory region of *Ppara* and analyzed their occupancy by GR in the fetal liver at E17 ([Figure 1G](#fig1){ref-type="fig"}). Chromatin immunoprecipitation (ChIP) using an antibody against GR revealed that the element spanning -1007 to -993 was preferentially occupied while the other two sites were not ([Figure 1H](#fig1){ref-type="fig"}). Upon treatment of primary hepatocytes with GR-targeting siRNA, the occupancy of GR at this putative site was significantly decreased as compared to treatment with non-targeting siRNA, thereby indicating the specificity of GR binding to this site ([Figure 1H](#fig1){ref-type="fig"}). Binding of GR to this putative GRE also followed the ontogenic pattern of *Ppara* expression in the fetal liver (Compare [Figure 1I](#fig1){ref-type="fig"} with [Figure 1B](#fig1){ref-type="fig"}). Therefore, PPARα is a direct target of GR in the fetal liver and its expression parallels that of GR in later stages of fetal development. These findings reveal a novel endocrine GR-PPARα axis in the regulation of the fatty acid (FA) catabolic machinery just before birth.

PPARα controls the prenatal lipid catabolic machinery {#s2-2}
-----------------------------------------------------

We next performed microarray analysis on gene expression in the fetal and neonatal *Ppara*^+/+^ and *Ppara*^-/-^ livers. PPARα-dependent fold changes in gene expression were higher in the term fetuses than in suckling pups, revealing major transcriptional PPARα activities just before delivery ([Figure 2A](#fig2){ref-type="fig"}; [Figure 2--- figure supplement 1A,B](#fig2s1){ref-type="fig"}). We found 915 and 425 down-regulated genes in *Ppara*^-/-^ liver at E19.5 and postnatal day 2 (P2), respectively ([Figure 2A](#fig2){ref-type="fig"}). Many of the differentially expressed genes were preferentially regulated in either the prenatal or postnatal liver, suggesting the involvement of distinct metabolic pathways at these two time points ([Figure 2A,B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}; [Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}, SD12). Genes preferentially controlled by PPARα in fetal liver (e.g., *Pex19, Slc25a20, Cpt2*, and *Fabp1*) relate to peroxisome biogenesis and FA shuttling−two upstream steps essential for FA catabolism ([Figure 2B,C](#fig2){ref-type="fig"}). Genes encoding the peroxisomal and mitochondrial enzymatic core of β- and ω-FAO, such as *Acox1, Acaa2, Acadl, Acadvl, Acsl1*, and *Cyp4a14*, were prenatally and/or postnatally controlled by PPARα ([Figure 2B,C](#fig2){ref-type="fig"}). In contrast, genes encoding the liver-secreted adaptive effectors of lipid catabolism (e.g., *Fgf21)* and xenobiotic-detoxifying enzymes (e.g., *Ugt3a1, Ces1g, Adh4, Ces3a, Sult2a1*) were only stimulated by PPARα postnatally ([Figure 2B,C](#fig2){ref-type="fig"}). Focused gene expression profiling further confirmed that genes encoding the rate-limiting enzymes involved in FA shuttling, mitochondrial and peroxisomal FA β-oxidation, and microsomal FA ω-oxidation were concomitantly down-regulated in *Ppara*^-/-^ liver before and/or after birth ([Figure 2C](#fig2){ref-type="fig"}). Lack of PPARα also resulted in fetal liver in an up-regulation of other nuclear receptors and their target genes involved in lipid metabolism ([Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}).10.7554/eLife.11853.004Figure 2.PPARα is a functional transcription factor in the term fetus.(**A**) Heat map of genes significantly altered at E19.5 (left panel) or P2 (right panel) in *Ppara^-/-^* livers (red: up-regulation; blue: down-regulation). Genes were grouped by fetal (E19.5) or postnatal (P2) expression and ordered by strength of regulation based on the logarithmic fold change (log~2~FC). (**B**) Gene ontology summarizing prenatal and postnatal PPARα-mediated regulation of metabolic pathways. (**C**) mRNA levels of representative PPARα target genes with differential fetal (E19.5) and postnatal (P2) regulation in *Ppara*^-/-^ and *Ppara*^+/+^ livers. *Slc25a20*: carnitine translocase; *Cpt2*: carnitine palmitoyltransferase 2; *Fabp1*: fatty acid binding protein 1; *Pex19*: peroxisome biogenesis factor 19; *Acox1*: peroxisomal acyl-CoA oxidase 1; *Cyp4a14*: cytochrome P450 4A14; *Fgf21*: fibroblast growth factor 21; *Angptl4*: angiopoietin-like protein 4; *Acaa2*: acetyl-CoA acyltransferase 2; *Acadl*: acyl-CoA dehydrogenase, long chain; *Acadvl*: acyl-CoA dehydrogenase, very long chain; *Acsl1*: acyl-CoA synthetase, long-chain family member 1. Data are presented as mean ± SEM; n = 6, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. wild-type controls; *^\#^*p\<0.05, ^\#\#^p\<0.01, ^\#\#\#^p\<0.001 vs. respective E19.5 samples. (**D**) Flow cytometric analyses of hepatoblasts (DLK^+^) and hepatocytes (CK18^+^) in fetal livers at E19.5. (**E**) mRNA expression levels of *Nr3c1, Ppara*, and PPARα target genes involved in peroxisome biogenesis (*Pex19*), peroxisomal and mitochondrial FAO (*Acox1, Acaa2, Acadl, Acadvl*, and *Acsl1*) in sorted fetal hepatoblast and hepatocyte fractions. Glycolytic genes (e.g., *Gc*k and *Hk1*) were also investigated in parallel with oxidative genes. *Nr3c1*: glucocorticoid receptor; *Ppara*: peroxisome proliferator-activated receptor α; ud: undetermined; *Gck*: glucokinase; *Hk1*: hexokinase 1. Data are presented as mean ± SEM; n = 4, \*p \<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. wild-type controls.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.004](10.7554/eLife.11853.004)10.7554/eLife.11853.005Figure 2---source data 1.A list of PPARα-regulated genes and pathways in prenatal and neonatal livers.The dataset provides a list of PPARα-regulated genes (**A**) and pathways (**B**) in E19.5 and P2 mouse livers. Significant genes based on a false discovery rate \< 0.05 were classified as regulated at both E19.5 and P2, in E19.5 only, or P2 only. The logarithmic fold change (logFC) cut-off value was set at 1.3. For each group, the significant enrichment of underlying KEGG, GO, and Reactome curated pathways was determined from the hypergeometric distribution and corrected for multiple comparisons.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.005](10.7554/eLife.11853.005)10.7554/eLife.11853.006Figure 2---figure supplement 1.PPARα deficiency leads to compensatory up-regulation of genes.(**A**) Venn diagram depicting the number of up-regulated genes in the *Ppara^-/-^*liver with overlapping PPARα regulation (false discovery rate \<0.05) before (E19.5) and after (P2) birth. The absolute fold change cut-off value was set at 1.3. (**B**) Heat map of genes significantly altered at E19.5 (left panel) or P2 (right panel) in *Ppara^-/-^* livers (red: up-regulation; blue: down-regulation). Genes were grouped by fetal or postnatal expression and ordered by strength of PPARα regulation based on the logarithmic fold change (logFC). (**C**,**D**) Up-regulated and down-regulated nuclear receptors and co-regulators (**C**) and nuclear receptor target genes (**D**) in *Ppara^-/-^*livers.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.006](10.7554/eLife.11853.006)

Since there is a heterogeneous population of undifferentiated hepatoblasts and differentiated hepatocytes in the liver at E19.5, we next determined whether one of these two cell populations was predominantly affected by the PPARα-dependent changes in gene expression. Using antibodies against hepatoblast- and hepatocyte-specific markers (i.e., Delta-Like Homolog 1 (DLK) and cytokeratin 18 (CK18), respectively), we performed flow cytometric analyses on the cells extracted from *Ppara*^+/+^ and *Ppara*^-/-^ livers at E19.5. Upon cell sorting, we specifically recovered the DLK^+^ and CK18^+^ fractions. Firstly, we showed that PPARα deficiency only led to marginal changes in these two hepatic cell populations ([Figure 2D](#fig2){ref-type="fig"}). Secondly, we determined the mRNA expression of *Nr3c1, Ppara* and the target genes of PPARα in these cells. Our results indicated that both *Ppara*^+/+^ hepatoblasts and hepatocytes similarly contributed to the expression of these genes ([Figure 2E](#fig2){ref-type="fig"}). Notably, we observed a modest but not significant upward trend in the expression of oxidative genes (e.g., *Acox1, Acaa2, Acadl*, and *Acadvl*) and a downward trend in the expression of glycolytic genes (e.g., *Gck* and *Hk1*) in the *Ppara*^+/+^ hepatocytes compared to hepatoblasts, possibly suggesting a more pronounced oxidative program in hepatocytes ([Figure 2E](#fig2){ref-type="fig"}). In contrast, the expression of these genes was concomitantly down-regulated in *Ppara*^-/-^ hepatoblasts and hepatocytes, thereby highlighting the pivotal role of PPARα in glycolytic and oxidative metabolism in both cell types.

Consistent with our gene expression studies, *Ppara*^-/-^ fetal livers had reduced numbers of peroxisomes and mitochondria compared to wild-type littermates at E19.5 ([Figure 3A](#fig3){ref-type="fig"}). However, only the mitochondria numbers but not the peroxisome numbers varied between the two groups at P2 ([Figure 3B](#fig3){ref-type="fig"}), underscoring the crucial role of mitochondrial FAO in PPARα-mediated lipid catabolism after birth. We next measured mitochondrial membrane potential (∆~Ψm~) and intracellular reactive oxygen species (ROS) production levels which are two common parameters used in assessing mitochondria health and functions ([@bib56]). Interestingly, we observed a much lower ∆~Ψm~ and a markedly increased intracellular ROS level in *Ppara*^-/-^ primary hepatocytes at P2 ([Figure 3C,D](#fig3){ref-type="fig"}), indicative of mitochondria dysfunction at this stage. However, there was no discernible difference in ∆~Ψm~ between *Ppara*^+/+^ and *Ppara*^-/-^ hepatocytes at E19.5 despite that a slight increase in the intracellular ROS level was observed in the latter. These findings suggest that an increased ROS production in cells likely precedes the loss of ∆~Ψm~ and mitochondria dysfunction, consistent with a previous report of a similar mitochondrial disorder associated with the dysfunctions of the respiratory chain components ([@bib37]). Indeed, respiratory chain-mediated ATP production in *Ppara*^-/-^ hepatocytes was approximately 35--50% of the levels measured in both prenatal and postnatal wild-type livers ([Figure 3C](#fig3){ref-type="fig"}). Substantiating these findings, a reduction of \~2.3-fold was observed in the basal oxygen consumption rate in *Ppara*^-/-^ primary hepatocytes from both E19 and P2 livers ([Figure 3D,E](#fig3){ref-type="fig"}). In the presence of FA (i.e., palmitate), the oxygen consumption rate significantly increased in *Ppara*^+/+^ hepatocytes but remained very similar in *Ppara*^-/-^ hepatocytes, indicating a deficiency in the activation of FAO in the latter ([Figure 3D,E](#fig3){ref-type="fig"}). The addition of etomoxir, an inhibitor of carnitine palmitoyltransferase 1, resulted in significant inhibition of mitochondrial β-FAO in *Ppara*^+/+^ but not in *Ppara*^-/-^ hepatocytes. *Ppara*^+/+^ hepatocytes exhibited a robust mitochondrial respiratory capacity of \~40% at both time points ([Figure 3E](#fig3){ref-type="fig"}). In contrast, only \~25% and \~11% of the total oxygen consumption rate were attributed to mitochondrial β-FAO in *Ppara*^-/-^ hepatocytes from E19 and P2 livers, respectively. Thus, these results provide evidence that PPARα-dependent respiration occurs in the term fetus. The higher expression of FA catabolic genes in fetal liver just before birth may prime the liver for the upcoming postnatal energy demand or point to an unknown role of fetal FAO. Therefore, we investigated whether the above defects in *Ppara*^-/-^ hepatocytes contribute to any phenotype in the fetal and neonatal liver.10.7554/eLife.11853.007Figure 3.Defective mitochondrial function, fatty acid oxidation and energy production in *Ppara*^-/-^ hepatocytes.(**A**,**B**) Flow cytometric analyses of intracellular peroxisomes and mitochondria in primary hepatocytes isolated from *Ppara*^-/-^ and *Ppara*^+/+^ livers at E19.5 (**A**) and P2 (**B**) using Alexa Fluor 488-labeled antibodies against peroxisome membrane protein 70 and Mitotracker Red, respectively. (**C**,**D**) Flow cytometric analyses of mitochondrial membrane potential (∆~ΨM~) (**C**) and intracellular ROS (**D**) in primary hepatocytes isolated from *Ppara*^-/-^ and *Ppara*^+/+^ livers at E19.5 and P2 using tetramethylrhodamine, ethyl ester (TMRE) and 2',7'-dichlorofluorescin diacetate (DCFDA), respectively. (**E**) ATP production in primary hepatocytes isolated from *Ppara*^-/-^ and *Ppara*^+/+^ livers (n = 4 per group) in the presence of glucose (+Glu), galactose (+Gal), or rotenone (+Rot, a mitochondrial electron transport chain complex I inhibitor) as a negative control. Values represent arbitrary bioluminescence units normalized to the number of viable cells. (**F**,**G**) Oxygen consumption rates (OCRs) in primary hepatocytes isolated from *Ppara*^-/-^ and *Ppara*^+/+^ livers in the presence or absence of palmitate and etomoxir, a mitochondrial β-oxidation inhibitor. Data are presented in time-lapse (**F**) and treatment end points (**G**) at 15 min for basal respiration, 50 min for palmitate treatment, and 80 min for palmitate cum etomoxir treatment. Data represent mean ± SEM; n = 3--9 unless otherwise stated, \*\*p\<0.01, \*\*\*p\<0.001 vs. wild-type controls; ^\#\#\#^p\<0.001 vs. no treatment group; ^§§§^p\<0.001 vs. palmitate treatment group (two-tailed Mann-Whitney test).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.007](10.7554/eLife.11853.007)

PPARα is required for protection against neonatal hepatic steatosis {#s2-3}
-------------------------------------------------------------------

Gross examination and histological analysis of the fetal *Ppara^-/-^ *livers at E19.5 did not reveal any discernible differences when compared with *Ppara^+/+^*controls. However, after birth, steatosis developed in *Ppara^-/-^ *livers at P2 but not in *Ppara^+/+^*livers ([Figure 4A,B](#fig4){ref-type="fig"}). Compared to *Ppara*^+/+^ littermates, *Ppara*^-/-^ pups displayed an enlarged and pallid liver with neutral lipid accumulation demonstrated by Oil Red O staining ([Figure 4A,B](#fig4){ref-type="fig"}). *Ppara*^-/-^ livers contained significantly higher levels of triglycerides and cholesterol ester at P2 with a concomitant increase in blood triglycerides ([Figure 4D--F](#fig4){ref-type="fig"}). In contrast, *Ppara*^-/-^ pups also exhibited markedly reduced serum β-hydroxybutyrate levels (i.e., hypoketonemia) and impaired essential FA profiles ([Figure 4G](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). All of these anomalies were absent in *Ppara*^-/-^ fetuses at E19.5. Interestingly, the postnatal phenotype of liver steatosis observed in *Ppara*^-/-^ pups spontaneously and gradually resolved at P15, coinciding with the suckling-to-weaning transition period when carbohydrate-rich food gradually replaces the lipid-rich milk ([Figure 4---figure supplement 1C,D](#fig4s1){ref-type="fig"}). These findings suggest that the neonatal steatosis observed in *Ppara*^-/-^ pups may be attributed to the ingestion of milk lipids.10.7554/eLife.11853.008Figure 4.PPARα deficiency leads to congenital hepatic steatosis after birth.(**A**) Photographs showing dissected *Ppara*^-/-^ and *Ppara*^+/+^ pups (*left*) and livers (*right*). The pallid liver of a *Ppara*^-/-^ pup is indicated by an arrow. The white content of the stomach indicates milk ingestion. (**B**) Representative Oil Red O-stained liver sections counterstained with methylene blue. Scale bars = 100 μm. (**C**--**G**) The Mean body weight (**C**), triglyceride (**D**) and cholesterol ester (**E**) contents of the liver, and serum levels of triglyceride (**F**) and β-hydroxybutyrate (β-OHB) (**G**). Data are presented as mean ± SEM; n = 6, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. wild-type controls; ^\#^p\<0.05 vs. respective E19.5; ns, not significant (two-way ANOVA with Bonferroni post-hoc analysis).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.008](10.7554/eLife.11853.008)10.7554/eLife.11853.009Figure 4---figure supplement 1.Postnatal lipid catabolic derangements in *Ppara^-/-^*pups.(**A**,**B**) Boxplots showing the ω-3 (**A**) and ω-6 (**B**) indexes of the P2 livers calculated from the ratios of docosahexaenoic acid to α-linolenic acid and arachidonic acid to linoleic acid, respectively. Boxes indicate the 25th to 75th percentiles and whiskers represent the full range; n = 16, \*\*\*p\<0.001 (two-tailed Mann-Whitney test). (**C**) Oil Red O staining of cryosections prepared from the *PPARα^-/-^ *liver at the indicated postnatal days. Note the onset and the progressive recovery of hepatic steatosis in *Ppara^-/-^ *mice from P2 to P15. (**D**) Liver triglyceride content measured by gas chromatography-high performance liquid chromatography; n = 4--6, \*\*p\<0.01, \*\*\*p\<0.001 vs. wild-type controls; ns, not significant (two-tailed Mann-Whitney test). (**E**--**H**) Ten-day high-fat weaning challenge in 5-day-old *Ppara^+/+^*and *Ppara^-/-^*pups. Representative images of the Oil Red O-stained liver sections after counterstaining with methylene blue are shown (**E**). Right-most panel shows the dissected livers at P15 after the challenge. Note the pallid color of *Ppara^-/-^*liver. Scale bars = 100 μm. Wet liver weight (**F**), liver triglyceride levels (**G**), and serum triglyceride levels (**H**) measured in P15 pups fed the control (Ctrl) or high-fat diet (HFD). (**I**) Oil Red O staining of cryosections prepared from the liver of hepatocyte-specific knockout of PPARα (*Ppara^fl/fl^Alb^Cre/+^*) and control (*Ppara^fl/fl^*) pups at postnatal day three (P3). Scale bars = 100 μm. Bars represent means ± SEM; n = 4--6, \*\*p\<0.01 vs. wild-type controls under the same dietary treatment (two-way ANOVA with Bonferroni post-hoc analysis).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.009](10.7554/eLife.11853.009)10.7554/eLife.11853.010Figure 4---figure supplement 2.Anaplerotic compensation for defective oxidative metabolism and ketogenesis in suckling *Ppara^-/-^*pups.(**A**,**B**) Body weight (**A**) and plasma glucose levels (**B**) of *Ppara^+/+^*and *Ppara^-/-^*pups at the indicated postnatal days. (**C**) Alanine aminotransferase (ALT) activity measured in liver lysates at P2. (**D**) Gluconeogenesis pathway in *Ppara^-/-^*liver at P2 with the supply of pyruvate through the anaplerotic metabolism of alanine indicated. (**E**) The affected amino acid oxidation pathways in *Ppara^-/-^*liver at P2. Colors indicate up-regulation (red) or down-regulation (blue) of genes identified by microarray analysis. The up-regulated genes are *Hal* (1), *Uroc1*(2), *Amdhd1* (3), *Ftcd* (4), *Glud* (5), *Pycr* (6), *Oat* (7), *Fah* (8), *Asl* (9), *Ass1* (10), *Got2* (11), *Got1* (12), *Sds* (13), *Cth* (14), *Cbs* (15), *Cdo1* (16), *Got1* (17), *Sds* (18), *Gpt* (19), *Pcx* (20). The down-regulated genes are *Ehhadh* (21,22,24), *Hibch* (23), *Hmgcs2* (25), *Hmgcl* (26). (**F**,**G**) Body weight (**F**) and blood glucose (**G**) of P2pups before and after daily intraperitoneal injections of 30 mg/kg L-cycloserine for two days (P4), three days (P5), and four days (P6). Bars represent means ± SEM; n = 4--6, \*p\<0.05, \*\*p\<0.01 vs. wild-type controls (two-way Mann-Whitney test).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.010](10.7554/eLife.11853.010)

Pups begin to nibble solid food in their second week, before weaning. To test whether the change in food composition that occurs at weaning is responsible for the reduction in the fatty liver phenotype as observed in *Ppara^-/-^*pups after P5-6, we performed a 10-day high-fat, low-carbohydrate diet challenge starting just before P5 and continuing into the suckling-to-weaning transition period. After the high-fat diet (HFD) challenge, the occurrence of liver steatosis was reenacted at P15 in *Ppara^-/-^* mice which consistently exhibited significantly higher liver weight, hepatic and serum triglyceride levels ([Figure 4---figure supplement 1E--H](#fig4s1){ref-type="fig"}). In contrast, liver steatosis was absent in the *Ppara^+/+^* counterparts fed the same diet as well as in mice fed the control diet ([Figure 4---figure supplement 1E-- H](#fig4s1){ref-type="fig"}). Furthermore, we also demonstrated in hepatocyte-specific *Ppara*^-/-^ mice (i.e., *Ppara^fl/fl^Alb^Cre/+^*) the presence of liver steatosis at P3, thereby confirming that the phenotypes observed in *Ppara*^-/-^ mice is most likely due to the hepatocyte-specific effects ([Figure 4--- figure supplement 1I](#fig4s1){ref-type="fig"}) ([@bib40]). Taken together, PPARα deficiency leads to lower mitochondria numbers, defective FA oxidative metabolism, and aberrant mitochondria functions which collectively contribute to the development of liver steatosis and hypoketonemia in *Ppara^-/-^* neonates as a result of their inability to metabolize milk lipids.

An effective hepatic FAO is necessary to support hepatic de novo ketogenesis and gluconeogenesis by providing essential co-factors such as acetyl-CoA and/or NADH ([@bib24]). This notion is consistent with the presence of hypoketonemia in *Ppara^-/-^* neonates with defective hepatic FAO. Interestingly, we found that *Ppara^-/-^* pups were able to maintain a body weight increase similar to their *Ppara^+/+^* littermates ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), suggesting that *Ppara^-/-^* neonates harnessed energy required for normal growth from fuels other than ketone bodies and lipids. Furthermore, we did not detect any differences in the plasma glucose levels between the two genotypes during the suckling period from P2 to P15 ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). This was rather surprising since *Ppara^-/-^* neonates were previously reported to exhibit hypoglycemia at P1 due to impaired gluconeogenesis from glycerol ([@bib14]). This finding prompted us to check whether the gluconeogenesis pathway is modified in the *Ppara*^-/-^ liver at P2. Based on our microarray data, we found that most of the genes (e.g., *Gpt, Pck1*, and *G6pc*) encoding the rate-liming enzymes involved in this pathway were up-regulated in parallel with a down-regulation of the rate-limiting genes involved in glycolysis (e.g., *Gck, Hk1*, and *Gpd2*) ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). We also detected in the *Ppara*^-/-^ liver a significantly elevated level of alanine aminotransferase (ALT), which is encoded by *Gpt* ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}). ALT is an enzyme that catalyzes the transfer of amino groups to form the hepatic metabolite oxaloacetate, an intermediate substrate in the tricarboxylic acid (TCA)/Krebs cycle, which can be used for gluconeogenesis. Thus, we postulated that an increased anaplerotic oxidation of amino acids may be an alternative pathway engaged to maintain gluconeogenesis and to supply glucose as an energy source for normal growth in *Ppara*^-/-^ neonates when the FAO capacity was impeded in the absence of PPARα. Indeed, most of the rate-limiting enzymes involved in amino acid oxidation (except for valine, leucine, and isoleucine) were concomitantly up-regulated in *Ppara*^-/-^ liver at P2 ([Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"}). Up-regulation of these genes would provide some of the intermediate substrates of the TCA cycle, such as α-ketoglutarate, fumarate, and oxaloacetate, which could be used for gluconeogenesis ([Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"}). Importantly, selective inhibition of ALT by intraperitoneal injection of L-cycloserine led to decoupling of amino acid oxidation from gluconeogenesis and ultimately resulted in stunted postnatal growth and hypoglycemia in *Ppara*^-/-^ pups ([Figure 4---figure supplement 2F,G](#fig4s2){ref-type="fig"}). In short, we conclude that PPARα functions both as a prenatally anticipatory and postnatally adaptive regulator of lipid catabolism, ultimately protecting the postnatal liver against a rapid insurgence of steatosis by promoting the use of milk lipids as an energy source.

An epigenetic switch controls a subset of PPARα target genes {#s2-4}
------------------------------------------------------------

How PPARα target genes are controlled at different stages of metabolic ontogenesis remains unclear. For instance, the genes (e.g., *Acox1*) involved in the anticipatory functions of PPARα (i.e., FAO) are stimulated in the fetus, but the adaptive regulators of lipid catabolism, such as the liver-secreted FGF21, were markedly stimulated by PPARα only after birth ([Figures 2C](#fig2){ref-type="fig"},[5A](#fig5){ref-type="fig"}). The binding of PPARα to the peroxisome proliferator response element (PPRE) in the promoter of *Acox1* and *Cyp4a14* (both genes are indicators for PPARα activation) ([@bib59]; [@bib2]), as well as Pol2 recruitment to their respective TSS, occurs before birth and results in increased expression of these genes ([Figure 5C,D](#fig5){ref-type="fig"}). This stimulation correlates with higher *Ppara* TSS activity and mRNA levels during hepatic ontogenesis ([Figure 1B,C](#fig1){ref-type="fig"}). Despite having comparable PPARα occupancy in the *Fgf21, Acox1*, and *Cyp4a14* promoters before birth, the recruitment of Pol2 to the *Fgf21* TSS was markedly delayed until after birth at P2, and then gradually increased thereafter ([Figure 5D](#fig5){ref-type="fig"}).10.7554/eLife.11853.011Figure 5.A temporal dichotomy in the regulation of PPARα target genes before and after birth.(**A**) Immunoblots showing the ontogenic expression of cytoplasmic and nuclear GR, HDAC3, PPARα, and its target genes, including ACOX1, Cyp4A14, FGF21, and full-length (FL)-ANGPTL4, in *Ppara*^-/-^ and *Ppara*^+/+^ livers. U2AF65 and β-tubulin were used as loading controls for nuclear and cytoplasmic proteins, respectively. (**B**--**D**) Enrichment of the DNA fragment containing the PPAR response element (PPRE) (left panels) on the ACOX1 (**B**), Cyp4A14 (**C**), and FGF21 (**D**) promoters or their respective TSS (right panels) using anti-PPARα and anti-Pol2 antibodies or pre-immune IgG. Data are presented as mean ± SEM; n = 4--6, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. untreated wild-type controls (two-tailed Mann-Whitney test).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.011](10.7554/eLife.11853.011)

Based on these observations, we postulated that other mechanisms may be involved in the differential Pol2 recruitment and promoter transactivation of these PPARα target genes. At E19.5, we found increased active histone marks (i.e., AcH4 and H3K4me3) near the TSS of *Acox1* and *Cyp4a14*, which correlated with a reduced enrichment of repressive histone marks (i.e., H3K9me3 and H3K27me3) ([Figure 6A,B](#fig6){ref-type="fig"}). At P2, the enrichment of active histone marks at the TSS of *Acox1* and *Cyp4a14* decreased with a concomitant increase in repressive histone marks, but this was not observed for *Fgf21* ([Figure 6A--C](#fig6){ref-type="fig"}). HDAC3 has been reported to repress hepatic *Fgf21* expression ([@bib28]; [@bib19]; [@bib3]; [@bib20]).In line with these reports, we observed a higher occupancy of HDAC3 at the *Fgf21* TSS at E19.5 compared to P2 ([Figure 6D](#fig6){ref-type="fig"}). We also found that the expression of *Angptl4* was also controlled by HDAC3 ([Figure 6E](#fig6){ref-type="fig"}). Interestingly, the lack of PPARα correlated with a \~10-fold increase in the HDAC3 occupancy at the *Fgf21* and *Angptl4* TSS ([Figure 6D,E](#fig6){ref-type="fig"}). In contrast, we detected negligible levels of HDAC3 recruitment to the *Cyp4a14* TSS ([Figure 6F](#fig6){ref-type="fig"}). Taken together, our results suggest that HDAC3-mediated histone modifications represent an additional mechanism by which certain PPARα target genes are temporally regulated.10.7554/eLife.11853.012Figure 6.PPARα-mediated regulation of *Fgf21* expression is dictated by the occupancy of HDAC3 on its promoter.(**A**--**C**) Enrichment of the DNA fragment containing the ACOX1 (**A**), Cyp4A14 (**B**), or FGF21 (**C**) TSS in primary hepatocytes isolated from *Ppara*^+/+^ pups using antibodies against acetyl-histone four (AcH4), trimethylated histone three at lysine four (H3K4me3), lysine nine (H3K9me3), lysine 27 (H3K27me3), or pre-immune IgG (Ctrl IgG) and evaluated by real-time qPCR. (**D**--**F**) Enrichment of the DNA fragment containing the FGF21 (**D**), ANGPTL4 (**E**), or Cyp4A14 (**F**) TSS in primary hepatocytes isolated from *Ppara*^-/-^ and *Ppara*^+/+^ pups with or without WY-14643 treatment in pregnant dams using anti-HDAC3 antibodies or control IgG. Data are presented as mean ± SEM; n = 4--6, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. untreated wild-type controls unless otherwise indicated (two-tailed Mann-Whitney test).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.012](10.7554/eLife.11853.012)

β-hydroxybutyrate induces *Fgf21* expression via HDAC3 inhibition {#s2-5}
-----------------------------------------------------------------

Previous studies indicate that milk lipids and hydroxymethylglutaryl-coenzyme A synthase 2 (HMGCS2) activity are required for *Fgf21* expression ([@bib28]; [@bib60]).We hypothesized that PPARα-dependent production of ketone bodies, particularly β-hydroxybutyrate, which was \~seven-fold higher in neonates than fetuses ([Figure 4G](#fig4){ref-type="fig"}), may activate postnatal gene expression by alleviating the repressive role of class I HDACs ([@bib51]).To test this possibility, we treated *Ppara^+/+^*liver explants from E19.5 pups with β-hydroxybutyrate, sodium butyrate (a known HDAC3 inhibitor), and trichostatin A, a selective inhibitor of class I and class II HDACs. Activation of the *Fgf21* transcriptional activity was dependent on both the activation of PPARα and HDAC3 inhibition through butyrate or β-hydroxybutyrate treatment ([Figure 7A](#fig7){ref-type="fig"}). In particular, HDAC3 inhibition or PPARα activation alone did not cause a significant change in *Fgf21* induction. However, trichostatin A alone, regardless of PPARα activation, led to significantly higher expression of *Fgf21*, suggesting the involvement of a PPARα-independent pathway and other class I or class II HDACs in the regulation of *Fgf21* expression in addition to PPARα ([Figure 7A](#fig7){ref-type="fig"}). In contrast, the activity of AcH4 at the TSS of *Cyp4a14* and *Acox1* and the expression of these genes were not influenced by any of the treatments except the PPARα ligand WY-14643, thereby excluding the involvement of HDAC3 or other class I and class II HDACs in the regulation of their transcriptional activity ([Figure 7B,C](#fig7){ref-type="fig"}). These results suggest that milk lipids can affect the epigenetic status of the postnatal liver in which hepatic production of β-hydroxybutyrate acts as an inhibitor of HDAC3 that regulates *Fgf21*.10.7554/eLife.11853.013Figure 7.β-hydroxybutyrate acts as an endogenous inhibitor of HDAC3 to activate *Fgf21* expression upon milk suckling.(**A**--**C**) Ex vivo liver explants isolated from *Ppara*^+/+^ fetuses at E19.5 were used to study the effects of butyrate, β-hydroxybutyrate, and trichostatin in the presence or absence of WY-14643 (WY) on PPARα target genes. *Left*: mRNA expression of *Fgf21* (**A**), *Cyp4a14* (**B**), and *Acox1* (**C**). *Right*: enrichment of the DNA fragment containing the FGF21 (**A**), Cyp4A14 (**B**), or ACOX1 (**C**) TSS after chromatin immunoprecipitation (ChIP) using antibody against acetyl-histone 4 (AcH4). Data are presented as mean ± SEM; n = 6, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 vs. E19.5 samples without WY-14643 treatment (two-tailed Mann-Whitney test).**DOI:** [http://dx.doi.org/10.7554/eLife.11853.013](10.7554/eLife.11853.013)

Discussion {#s3}
==========

In mammals, the transition to extra-uterine life represents a sudden shift in the source of energy (i.e., from a carbohydrate-laden fetal diet to a high-fat, low-carbohydrate diet). The neonatal liver must coordinate hepatic FAO, gluconeogenesis, and ketogenesis in order to maintain bioenergetic homeostasis and to meet the metabolic demands associated with extra-uterine life which depends exclusively on milk ([@bib13]). In contrast to the carbohydrate-replete nutrient state experienced in utero, neonatal energy is dominated by PPARα-dependent transcriptional regulation of lipid catabolism. We found that this anticipatory regulation of PPARα activity and lipid metabolism is directly controlled by GR before birth.

Glucocorticoid hormones are crucial in the functional maturation of many key tissues, notably in preparation for birth ([@bib15]). The initiation of parturition is marked by short bursts of stress hormones ([@bib5]). We demonstrate that this short burst of glucocorticoids at the initiation of birth directly stimulate the GR-dependent transcription of PPARα and its lipid catabolic target genes, which in turn prepare neonates for the sudden shift to fat-rich milk diet as the primary source of energy ([Figure 8A,B](#fig8){ref-type="fig"}). Indeed, we previously demonstrated the GR-mediated hormonal induction of PPARα in adult hepatocytes ([@bib38]), while others showed that ligand-activated PPARα interferes with the recruitment of GR and Pol2 to the promoter of classical GRE-driven genes, inhibiting their transcription ([@bib6]). This is also consistent with our observation of a reduced expression of *Nr3c1* in *Ppara^-/-^* livers, implicating a reciprocal regulatory relationship between GR and PPARα.10.7554/eLife.11853.014Figure 8.Schematic illustrations of GR-mediated regulation of PPARα expression, HDAC3-dependent and -independent regulation of PPARα target genes before and after birth, and the affected liver metabolic processes with or without PPARα.(**A**) In fetal liver, hormone-activated GR binds to the GR response element (GRE) spanning -1007 to -993 within the PPARα promoter region to directly activate the transcription of *Ppara*. NTD: N-terminal domain, LBD: ligand-binding domain, DBD: DNA-binding domain. (**B**) At E19.5, direct binding of HDAC3 near the TSS of *Fgf21* leads to the repression of *Fgf21* transcriptional activity. Upon milk suckling, PPARα-dependent production of β-hydroxybutyrate from the neonatal liver alleviates the HDAC3-mediated repression of *Fgf21* by directly inhibiting the activity of HDAC3, permitting PPARα-dependent *Fgf21* expression. Activated GR leads to the stimulation of PPARα and its target genes in fetal liver, such as those involved in mitochondrial and peroxisomal fatty acid oxidation (FAO). After birth, the expression of PPARα target genes involved in mitochondrial FAO predominates the expression of genes involved in peroxisomal FAO, probably due to the higher long-chain fatty acid (LCFA) content than very-long-chain fatty acid (VLCFA) content in the milk. (**C**) Schematic illustration depicting the affected processes of hepatic metabolism in the presence and absence of PPARα. Green boxes/arrows indicate increments; reds indicate decrements.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.014](10.7554/eLife.11853.014)

We indicate that lipid catabolic target genes of PPARα, particularly those involved in mitochondrial, peroxisomal, and microsomal oxidation, are switched on just before birth in anticipation of a postpartum lipid-rich meal. In the neonatal liver, however, we show that mitochondrial β-oxidation prevails as the major contributor to the neonatal oxidative capacity and protects against hepatic steatosis when faced with a sudden surge in dietary fat. Our findings are consistent with the notion that mitochondrial FAO represents the dominant metabolic pathway whereas peroxisomal FAO assumes a relatively minor role ([@bib27]). Accordingly, long-chain FAs constitute more than 60% of the total FAs in animals and milk ([@bib52]), and their abundance makes them the only significant source of metabolic fuel for the mitochondrial, but not peroxisomal, β-oxidation system ([@bib46]). Moreover, decreased mitochondrial FAO has been considered one of the major contributing factors leading to liver steatosis ([@bib43]). Thus, we conclude that the concomitant presence of lipid content of milk, a lower number of mitochondria and overt mitochondrial dysfunctions jointly contributes to the development of liver steatosis in *Ppara^-/-^*neonates. Notably, mitochondrial dysfunctions were evident in *Ppara^-/-^* hepatocytes due to reduced ∆~ΨM~ and increased intracellular ROS levels. We postulate that an increased intracellular ROS level likely precedes the loss of ∆~ΨM~ and mitochondria dysfunction. As this oxidative stress condition continues to worsen after birth, perhaps induced by nutritional lipid as previously indicated ([@bib58]), reduced ∆~ΨM~ and ATP production ultimately ensue. This is in agreement with a previous report of a similar mitochondrial disorder associated with the dysfunctional respiratory chain components ([@bib37]). Particularly, the increased intracellular ROS levels observed in *Ppara*^-/-^ hepatocytes may be due to the reduced clearance of ROS as evidenced by the down-regulation of genes coding for mitochondrial superoxide dismutase 2 (SOD2) and copper chaperone for SOD1 (a metalloprotein responsible for delivering copper as a co-factor to SOD1) before and/or after birth ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). This observation is consistent with the report that PPARα activation by agonist clofibrate stimulates SOD1 and catalase activities as part of the defense mechanisms against oxidative stress in the heart ([@bib30]).

Many of the PPARα-regulated genes involved in FAO have previously been shown to contain a PPRE in their promoter region and hence, recognized as direct PPARα target genes (Rakhshandehroo et al., 2010). This implicates that the reduced oxidative capacity observed in *Ppara^-/-^* mice was due to the lack of direct PPARα-mediated stimulatory effects rather than a cellular-autonomous metabolic adaptation in response to lower mitochondria numbers. As discovered by Semenkovich and[@bib45] co-workers ([@bib9], [@bib8]), newly synthesized FA by fatty acid synthase may also regulate glucose, lipid, and cholesterol metabolism by serving as endogenous activators of a distinct physiological pool of PPARα ligands in adult liver. However, we doubt that de novo synthesis of FA plays a predominant role in the regulation of PPARα activity during early postnatal period since insulin/glucagon ratio is low, which promotes FAO rather than de novo synthesis of FA ([@bib22]). Our recent work indicates that PPARα has little impact on the expression of lipogenic genes in normal conditions ([@bib40]). Moreover, an effective hepatic FAO is essential for the provision of acetyl-CoA and NADH to support hepatic de novo ketogenesis and gluconeogenesis ([@bib24]). This notion is consistent with the hypoketonemia and hypoglycemia in *Ppara^-/-^*neonates reported in this work and by Crawford and co-workers ([@bib14]). Notably, the hypoglycemic phenotype previously reported in *Ppara^-/-^*neonates by Cotter et al. happened at P1 due to a decreased hepatic gluconeogenesis from glycerol. However, we did not detect any sign of hypoglycemia in these mice starting from P2. This apparent discrepancy is likely attributable to the rapid (\~1 day) and dynamic adaptive functions of *Ppara^-/-^*neonatal liver in providing glucose as the primary source of energy required for postnatal growth and in maintaining glucose homeostasis. Our finding also supports the work of others indicating a preserved gluconeogenesis from glycerol in adult *Ppara*^-/-^ mice ([@bib63]). We elucidated that this cell-autonomous metabolic adaptation was enhanced in the absence of PPARα and mediated through the up-regulation of hepatic ALT and anaplerotic amino acid oxidation. Thus far, the mechanism behind the increased production and secretion of ALT in *Ppara^-/-^*neonatal liver still remains unclear. It is notable that *ALT2* expression is up-regulated under metabolic stress and that plasma and tissue ALT levels are elevated in response to endoplasmic reticulum (ER) stress ([@bib48]; [@bib33]). Interestingly, defective PPARα signaling has been reported to cause hepatic mitochondrial and ER stress in the pathogenesis of hepatic steatosis through reduced mRNA expression of the sarco/endoplasmic reticulum calcium ATPase (SERCA) ([@bib55]). In addition, our transcriptome analysis revealed a consistent reduction by \~1.2-fold in the expression of *Atp2a2*, which encodes SERCA, in *Ppara^-/-^* liver at E19.5 and P2 ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). Moreover, we also delineated that most of the rate-limiting enzymes involved in amino acid oxidation were concomitantly up-regulated in *Ppara^-/-^*neonatal liver to provide essential intermediate substrates in TCA/Krebs cycle required for gluconeogenesis. Hence, we speculate that de novo synthesis of glucose becomes the primary energy source in sustaining normal postnatal growth in *Ppara^-/-^*neonates as evidenced by the observed growth retardation upon decoupling of amino acid oxidation from gluconeogenesis. This is in conjunction with the failure of *Ppara^-/-^*neonatal liver in harnessing energy from ketone bodies and lipids due to defective mitochondrial functions. In parallel, the compensatory up-regulation of pyruvate carboxylase (Pcx) and other gluconeogenic genes in *Ppara^-/-^*neonates at P2 probably corresponds with a lower hepatic acetyl-CoA level, as supported by a recent report that hepatic acetyl-CoA acts as an allosteric regulator of Pcx ([@bib44]). Importantly, these findings in *Ppara^-/-^*mice illustrate the tremendous flexibility of the neonatal liver in coordinating ketogenesis, FAO, and gluconeogenesis so as to meet the energy demand required for normal growth especially when faced with an energy crisis caused by defective oxidative metabolism and hypoketonemia.

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) is one of the rate-liming enzymes involved in ketogenesis. *Hmgcs2* contains a PPRE in its promoter region and is under the direct transcriptional control of PPARα ([@bib47]). HMGCS2 has been shown to induce mitochondrial FAO and FGF21 expression, possibly via a SIRT1-dependent mechanism ([@bib60]). Furthermore, *Hmgcs2* mRNA expression peaks 16 hr after birth and coincides with a decline in *Acox1* mRNA expression thereafter ([@bib64]; [@bib50], [@bib49]). These reports substantiate our findings of preferential activation of mitochondrial FAO at birth. Our results also support the in vivo finding that β-hydroxybutyrate is a potent physiological inhibitor of HDAC3 ([@bib51]), suggesting that PPARα-mediated activation of HMGCS2 and β-hydroxybutyrate production precedes the PPARα-regulated production of FGF21. Similar to other PPARα target genes, we detected PPARα occupancy in the *Fgf21* promoter before birth, but its transcription is ultimately determined by the alleviation of HDAC3-mediated inhibition ([Figure 8B](#fig8){ref-type="fig"}). Thus, fatty acid catabolism provides β-hydroxybutyrate, which acts as a secondary signal to initiate the de-repression of the *Fgf21* promoter by HDAC3, allowing it to become PPARα responsive. It was previously indicated that HDAC-mediated histone deacetylation may inhibit transcription at the initiation and/or elongation step ([@bib61]). If the genes are loaded by Pol2 at the TSS, similar to what we observed at the *Fgf21* TSS upon PPARα agonistic activation, HDAC-mediated inhibition of transcription most likely happens at the elongation step although abortive initiation of the TSS bound Pol2 cannot be excluded. Our results suggest that PPARα activation induces the recruitment and assembly of a transcription initiation complex at the *Fgf21* TSS. However, the elongation of *Fgf21* mRNA transcript only ensues after alleviation of HDAC3 inhibition by β-hydroxybutyrate. Therefore, it is consistent with our findings that PPARα agonist has no effect on *Fgf21* mRNA or transcriptional activation in the absence of β-hydroxybutyrate.

Both human and mouse neonates exhibit mild ketogenic conditions during early postpartum period (0--1 day, 0.2--0.5 mmol/L), which further exacerbates after 5--10 days (0.5--1.1 mmol/L) ([@bib26]). We believe that it could be due to the use of lipids as preferred fuel for growth while the carbohydrate parts of milk (e.g., lactose and oligosaccharide−two main carbohydrates in milk) mainly contribute to brain growth (i.e., myelin synthesis) and gut microbiota nourishment ([@bib18]; [@bib11]). Further, the observed ketogenic condition may also be explained by the low insulin/glucagon ratio in early postpartum life ([@bib22]; [@bib21]; [@bib23]). We found that ketone bodies act as a hit that is important to prime PPARα-dependent expressions of *Fgf21* and *Angptl4* by modulating HDAC3 activity on their promoter. Both FGF21 and ANGPTL4 function as secreted systemic effectors of PPARα ([@bib4]; [@bib17]). However, unlike *Fgf21*, the expression of *Angptl4* has already begun in the fetal liver. This finding is congruent with the report that ANGPTL4 functions as a glucocorticoid-dependent gatekeeper of FA flux by inhibiting the activity of adipose tissue lipoprotein lipase during fasting ([@bib35]; [@bib17]). In fact, significant overlap exists between the bioenergetic challenges experienced during fasting and at birth. Liver-derived FGF21 acts as an endocrine regulator of ketogenesis, which links the phenotypes observed during fasting and in newborns ([@bib4]; [@bib28]). This concept is evident in *Ppara*^-/-^ mice, which have reduced plasma FGF21 levels. During fasting, the switch to a lipid-dominated nutrient supply provokes hypoketonemia, hypoglycemia, and hepatic steatosis in adult *Ppara*^-/-^ mice ([@bib34]; [@bib40]). In concordance with a recent report ([@bib14]), the shift to a high-fat, low-carbohydrate ketogenic diet in *Ppara*^-/-^ neonates results in steatosis similar to that observed in fasted adult *Ppara*^-/-^ mice. Notably, FGF21 has previously been shown to stimulate hepatic FAO and to prevent hepatic steatosis following ingestion of lipid-laden milk ([@bib62]). Hence, we believe that the physiological relevance of FGF21 induction in neonates after milk suckling relates to its role in metabolic regulation by stimulating lipid catabolism rather than a response to starvation or a low calorie condition which no longer exists upon milk ingestion. It is also important to note that the early human breast milk is not initially ketogenic due to the relatively high lactose content, which gradually decreases while the fat content increases as the milk matures over time ([@bib32]). In contrast, mouse milk is likely a ketogenic diet as evidenced by a previous report that early mouse milk comprises \~17% of fat and \~1.7% of lactose at P3 ([@bib25]). Therefore, direct translation of our findings to human situations needs to be cautioned for such differences in milk composition.

In summary, we provide evidence that prenatal expression of PPARα is under the direct control of GR. The GR-dependent PPARα activity is pivotal for the induction of hepatic FA catabolic genes, pointing to a novel anticipatory role of PPARα in the fetal liver in preparation for the efficient use of milk fat as an energy source. In addition, hepatic FA catabolism provides essential co-factors for the synthesis of ketone bodies such as β-hydroxybutyrate. Interestingly, ketone bodies act as a secondary signal that further activates PPARα-dependent regulation of the hepatokine FGF21. Therefore GR-PPARα axis may represent a critical signaling pathway in late gestation for the ability of mammalian newborns to use nutrients and maintain whole-body homeostasis. We conclude that in the absence of PPARα, a vicious cycle pertaining to the (i) lower mitochondria numbers, (ii) mitochondrial dysfunctions, (iii) impaired mitochondrial FA β-oxidation, (iii) hypoketonemia either due to a lack of direct PPARα stimulation of *Hmgcs2* or a lack of essential co-factors provided by functional FAO, (iv) lack of epigenetic activation of FGF21 by ketone bodies (e.g., β-hydroxybutyrate), and (v) a surge in nutritional lipids upon milk suckling, exists to concomitantly contribute to the development of hepatic steatosis in neonates ([Figure 8C](#fig8){ref-type="fig"}).

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

PPARα-null (*Ppara^-/-^*) and GR-null (*Nr3c1^-/-^*) mice were acquired from the Jackson Laboratory (Bar, Harbor, ME) and Nuclear Receptor Zoo (MGI: 95824, Strasbourg, France), respectively. These mice were given standard rodent chow diet (AIN93M, Specialty Feeds, Australia) ([Table 1](#tbl1){ref-type="table"}) and water ad libitum, maintained in a C57BL/6 background, and bred in our specific pathogen-free facilities by inter-crossing *Ppara*^+/-^ mice to obtain experimental wild-type and knockout pups in the same litter. This breeding strategy allowed the experimental mice to be exposed to the same gestational environment and ensured that pups received milk of the same nutritional content from the heterozygous dams. Pregnancy was timed based on vaginal plug formation. Pregnant dams approaching full-term were closely monitored and cesarean section performed to obtain fetuses at E19.5 or earlier (E13, E15, E17). Pups at P2 were timed based on the delivery day. Litters of 6--8 pups were used to minimize differences in milk availability verified by stomach inspection. All experimental protocols involving animals were reviewed and approved by the Veterinary Office of the Canton Vaud (SCA--EXPANIM, Service de la Consommation et des Affaires Vétérinaires, Epalinges, Switzerland) in accordance with the Federal Swiss Veterinary Office Guidelines and by the Institutional Animal Care and Use Committee (\#2013/SHS/866) in Singapore. The animal handling procedures were compliant with the *NIH Guide for the Care and Use of Laboratory Animals.*10.7554/eLife.11853.015Table 1.Standard chow diet formulation.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.015](10.7554/eLife.11853.015)**Manufacturer**: SPECIALITY FEEDS\
**Product ID**: AIN93M**Standard AIN93M rodent diet**A semi-pure diet formulation for laboratory rats and mice based on AIN-93M. This formulation satisfies the maintenance nutritional requirements of rats and mice. Some modifications have been made to the original formulation to suit locally available raw materials.We have evidence that vitamin losses and other changes to the diet can occur when irradiated at 25KGy. The diet SF08-020 has been formulated for irradiation. Please contact us for more information if the diet is to be irradiated.**Calculated nutritional parametersIngredients**Protein13.6%Casein (acid)140 g/kgTotal fat4.0%Sucrose100 g/kgTotal digestible carbohydrate as defined by FSANZ Standard 1.2.8\
64.8%\
Canola oil40 g/kgCellulose50 g/kgCrude fiber4.7%Wheat starch472 g/kgAD fiber4.7%Dextrinised starch155 g/kgDigestible energy15.1 MJ/kgDL methionine1.8 g/kg% Total calculated digestible energy from lipids9.0%Calcium carbonate13.1 g/kg% Total calculated digestible energy from protein15.0%Sodium chloride2.6 g/kgAIN93 trace minerals1.4 g/kg**Diet form and features**Potassium citrate1.0 g/kgSemi pure diet. 12 mm diameter pellets.Pack size 5 kg. Vacuum packed in oxygen impermeable plastic bags, under nitrogen. Bags are packed into cardboard cartons for protection during transit. Smaller pack quantity on request.Diet suitable for irradiation but not suitable for autoclave.Lead time 2 weeks for non-irradiation or 4 weeks for irradiation.Potassium dihydrogen phosphate8.8 g/kgPotassium sulphate1.6 g/kgCholine chloride (75%)2.5 g/kgAIN93 vitamins10 g/kg**Calculated amino acidsCalculated total vitamins**Valine0.90%Vitamin A (retinol)4000 IU/kgLeucine1.30%Vitamin D (cholecalciferol)1000 IU/kgIsoleucine0.60%Vitamin E (α-tocopherol acetate)75 mg/kgThreonine0.60%Vitamin K (menadione)1 mg/kgMethionine0.60%Vitamin C (ascorbic acid)None addedCystine0.05%Vitamin B1 (thiamine)6.1 mg/kgLysine1.00%Vitamin B2 (riboflavin)6.3 mg/kgPhenylanine0.70%Niacin (nicotinic acid)30 mg/kgTyrosine0.70%Vitamin B6 (pryridoxine)7 mg/kgTryptophan0.20%Pantothenic acid16.5 mg/kgHistidine0.42%Biotin200 μg/kg**Calculated total minerals**Folic acid2 mg/kgCalcium0.47%InositolNone addedPhosphorus0.35%Vitamin B12 (cyancobalamin)103 μg/kgMagnesium0.09%Choline1670 mg/kgSodium0.15%**Calculated fatty acid composition**Chloride0.16%Myristic acid 14:0No dataPotassium0.40%Palmitic acid 16:00.20%Sulphur0.17%Stearic acid 18:00.10%Iron75 mg/kgPalmitoleic acid 16:1No dataCopper6.9 mg/kgOleic acid 18:12.40%Iodine0.2 mg/kgGadoleic acid 20:1traceManganese19.5 mg/kgLinoleic acid 18:2 n60.80%CobaltNo dataα-Linolenic acid 18:3 n30.40%Zinc47 mg/kgArachidonic acid 20:4 n6No dataMolybdenum0.15 mg/kgEPA 20:5 n3No dataSelenium0.3 mg/kgDHA 22:6 n3No dataCadmiumNo dataTotal n30.45%Chromium1.0 mg/kgToal n60.76%Fluoride1.0 mg/kgTotal mono-unsaturated fats2.46%Lithium0.1 mg/kgTotal polyunsaturated fats1.21%Boron3.1 mg/kgTotal saturated fats0.28%Nickel0.5 mg/kgVanadium0.1 mg/kg[^2]

Tissue RNA isolation and quantitative real-time PCR {#s4-2}
---------------------------------------------------

Total RNA was extracted from liver samples using TRIzol reagent (Life Technologies, Carlsbad, CA) and purified using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The purified RNA was spectrophotometrically quantified and its quality assessed by measuring the absorbance ratios at 260 nm/280 nm and 260 nm/230 nm using Nanodrop Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). One microgram of mRNA was reverse-transcribed to cDNA using Superscript II Reverse Transcriptase (Life Technologies, Carlsbad, CA). The cDNA template was amplified by real-time PCR using iTaq SYBR Green Supermix (Bio-Rad, Hercules, CA). Relative mRNA levels were calculated using the comparative 2^-∆∆CT^ method after normalization to *36B4/RplP0* expression, which was used as an invariant control. The primer sequences used for real-time PCR were obtained from the Harvard PrimerBank (<http://pga.mgh.harvard.edu/primerbank>) and are provided in [Table 2](#tbl2){ref-type="table"}.10.7554/eLife.11853.016Table 2.Primer sequences for mouse genes used in quantitative real-time PCR.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.016](10.7554/eLife.11853.016)GeneForward primer (5'-3')Reverse primer (5'-3')Acaa2ATGTGCGCTTCGGAACCAAACAAGGCGTATCTGTCACAGTCAcetyl-coenzyme A acyltransferase 2/short chain-specific 3-ketoacyl-CoA thiolase (mitochondrial)AcadlTGCCCTATATTGCGAATTACGGCTATGGCACCGATACACTTGCAcyl-coenzyme A dehydrogenase, long chainAcadvlTGACCTTGGTGTTAGCGTTACCTGGGCCTTTGTGCCATAGAGAcyl-coenzyme A dehydrogenase, very long chainAcox1TCGAAGCCAGCGTTACGAGATCTCCGTCTGGGCGTAGGAcyl-CoA oxidase 1, palmitoylAcsl1ACCAGCCCTATGAGTGGATTTCAAGGCTTGAACCCCTTCTGAcyl-CoA synthetase, long chain family member 1Angptl4TCCAACGCCACCCACTTACTGAAGTCATCTCACAGTTGACCAAngiopoietin-like 4Cpt1aCTATGCGCTACTCGCTGAAGGGGCTTTCGACCCGAGAAGACarnitine palmitoyltransferase 1a (liver)Cpt2CAAAAGACTCATCCGCTTTGTTCCATCACGACTGGGTTTGGGTACarnitine palmitoyltransferase 2Cyp4a14TCATGGCGGACTCTGTCAATAGCAGGCGAAAGAAAGTCAGGCytochrome P450, family 4, subfamily a, polypeptide 14EhhadhACAGCGATACCAGAAGCCAGTGGCAATCCGATAGTGACAGCEnoyl-coenzyme A, hydratase/3-hydroxyacyl coenzyme A dehydrogenaseFabp1AAGGCAGTCGTCAAGCTGGCATTGAGTTCAGTCACGGACTTFatty acid bind protein 1 (liver)Fgf21CTGCTGGGGGTCTACCAAGCTGCGCCTACCACTGTTCCFibroblast growth factor 21GckAGACGAAACACCAGATGTATTCCGAAGCCCTTGGTCCAGTTGAGGlucokinaseNr3c1CCGGGTCCCCAGGTAAAGATGTCCGGTAAAATAAGAGGCTTGGlucocorticoid receptorHadhaAGCAACACGAATATCACAGGAAGAGGCACACCCACCATTTTGGHydroxyacyl-coenzyme A dehydrogenase, alpha subunitHadhbTGAATATGCACTGCGTTCTCATCCTTTCCTGGTACTTTGAAGGGHydroxyacyl-coenzyme A dehydrogenase, beta subunitHk1CGGAATGGGGAGCCTTTGGGCCTTCCTTATCCGTTTCAATGGHexokinase 1Fkbp51TTTGAAGATTCAGGCGTTATCCGGGTGGACTTTTACCGTTGCTCFK506 binding protein 51Pex19GACAGCGAGGCTACTCAGAGGCCCGACAGATTGAGAGCAPeroxisomal biogenesis factor 19PparaTCGGCGAACTATTCGGCTGGCACTTGTGAAAACGGCAGTPeroxisome proliferator activated receptor alphaSlc25a20GCGCCCATCATTGGAGTCACACACCAGATAACATCCCAGCSolute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 2036B4/RplP0CGAGGACCGCCTGGTTCTCGTCACTGGGGAGAGAGAGGRibosomal protein P0

ChIP assays {#s4-3}
-----------

Eight to ten livers were pooled, homogenized, and cross-linked with 1% formalin at room temperature for 5 min. The reaction was stopped with the addition of glycine and nuclei isolated by sucrose-density ultracentrifugation. The nuclei were sonicated to produce DNA fragments of \~500--1000 base pairs. Total chromatin was incubated with 10 μg of antibody overnight at 4°C and precipitated with 10 μl of blocked protein A-agarose beads (Life Technologies, Carlsbad, CA) at 4°C for 2 hr. After de-crosslinking, the DNA was purified and the enrichment quantified by quantitative real-time PCR, expressing the results as the percentage of input. Antibodies against RNA polymerase II (Pol2, \#sc-67318X), GR (\#sc-1004X), and pre-immune rabbit antibodies (\#sc-2027X) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against PPARα (\#AB2779), histone deacetylase 3 (HDAC3, \#AB7030), acetyl-histone 4 (AcH4), and trimethylated lysine 4 (H3K4me3, \#AB8580), lysine 9 (H3K9me3, \#AB8898), and lysine 27 (H3K27me3, \#AB6002) of histone 3 were from Abcam (Cambridge, MA). The primer sequences used for chromatin immunoprecipitation were provided in [Table 3](#tbl3){ref-type="table"}.10.7554/eLife.11853.017Table 3.Primer sequences for mouse genes used in chromatin immunoprecipitation.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.017](10.7554/eLife.11853.017)GeneForward primer (5'-3')Reverse primer (5'-3')ACOX1_TSSTCCCGGAAAGATCACGTGAACCTCCCCGAGCGGCTCCTCGCCAACOX1_PPRETAGCCAACGACAATGAACCCGGAAACCAGAAGGGAATGANGPTL4_TSSCCAGCAAGTTCATCTCGTCCTCCCTCCCACTCCCACACCCYP4A14_TSSATTCCCCCTCCCACAAGTAGCCCATGGTTAGTAGTTTCTGGACYP4A14_PPREAAGGAAAAGGCCACCGTCTATCCATCTCACTGAACTTTACCCFGF21_TSSATATCACGCGTCAGGAGTGGTCCCCAGCTGAGAAGACACTFGF21_PPREAGGGCCCGAATGCTAAGCAGCCAAGCAGGTGGAAGTCTPPARα_TSSGTTGTCATCACAGCTTAGCGCAGATAAGGGACTTTCCAGGTCPPARα_GRE\
(−1007 to −993)GGGACTCGGGGAACAAGCTGTGCGATCTAGGGAAGGGTGCGCCTTGGCGCGCACTCCPPARα_GRE\
(−2080 to −2066)CTTTCCTCTCAATACAGTCTGTCAAACAAAAGTTTTGTTTGTTTTGACTCTCTGTCCAGPPARα_GRE\
(−2953 to −2939)AAGGGTGAACACACTTTGTTTCCTGGATGTCCACCAGGGCAGGGGAAGTAGGTATT

Dexamethasone treatment {#s4-4}
-----------------------

E15 fetal liver explants were used for treatment with dexamethasone due to their relatively low PPARα activation status. Fresh liver sections (n = 6 per treatment group) were cultured in the presence of dexamethasone (0.1 μM, 1 μM, or 10 μM) for 24 hr. After treatment, total RNA was isolated and purified, and PPARα mRNA levels were measured by quantitative real-time PCR.

Primary hepatocyte isolation and culture {#s4-5}
----------------------------------------

Fetuses or pups were sacrificed by decapitation. The liver was removed, minced into fine consistency with a pair of scissors, and digested at 37°C with agitation at 115 rpm for 1 hr in 10 ml of sterile-filtered 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES):collagenase solution containing 0.1 M HEPES, 0.12 M NaCl, 50 mM KCl, 5 mM D-glucose, 1.5% bovine serum albumin (BSA), 1 mM CaCl~2~, and 10,000 activity units of type-I collagenase (Life Technologies, Carlsbad, CA). The cell suspension was filtered through a 100-μm nylon mesh (BD Falcon, Franklin Lakes, NJ) and collected in a 50-ml centrifuge tube. The suspension was centrifuged at 200 × g for 10 min to pellet the cells and the supernatant removed. Red blood cell (RBC) lysis solution was added to re-suspend the cells, followed by incubation at room temperature for 5 min. After RBC lysis, ice-cold PBS was added and the cell suspension filtered through a 40-μm nylon mesh (BD Falcon, Franklin Lakes, NJ) to remove cell clumps. Finally, the cell suspension was centrifuged at 200 ×g for 5 min to pellet the cells. For primary hepatocyte culture, the isolated mouse hepatocytes (2 × 10^5^ cells/per 9.5 cm^2^ well) were then cultured in DMEM containing 10% fetal calf serum (FCS) and 2 mM penicillin/streptomycin in 6-well plates coated with rat tail collagen (Corning, Tewksbury, MA).

siRNA-mediated knockdown of *Nr3c1* {#s4-6}
-----------------------------------

Primary hepatocytes were isolated and cultured as described above. Upon reaching a confluency of \~60%, the adherent cells were treated with 50 ng ON-TARGETplus NR3C1/GR-targeting SMARTpool siRNAs (L-045970-01-0005) or non-targeting pool (D-001810-10-05) (GE Dharmacon, Lafayette, CO) for 24 hr using transfection reagent DharmaFECT 1 as per the manufacturer's protocol. Cells were harvested for α-GR ChIP assays after 48 hr of incubation with complete medium. Successful knockdown was determined by reduced *Nr3c1* mRNA expression of at least 80% when compared with non-targeting siRNA treatment group.

Gene expression microarray and analysis {#s4-7}
---------------------------------------

RNA samples were randomly selected from three different litters for each genotype (n = 6). Total RNA was extracted from mouse liver using TRIzol reagent (Life Technologies, Carlsbad, CA) and further purified using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA quality measurements were performed using an Agilent 2100 bioanalyzer (Agilent Technologies, Waldbronn, Germany). Only samples with intact bands corresponding to the 18S and 28S rRNA subunits without contamination with chromosomal DNA and had an RNA integrity number \> 8.0 were selected for array hybridization. Hybridization was performed with Affymetrix Mouse Genome MoGene1.0 ST arrays according to the manufacturer's protocol and analyzed as described previously ([@bib39]).Briefly, the significant enrichment of underlying KEGG, GO, and Reactome curated pathways was determined from the hypergeometric distribution and corrected for multiple comparisons using Broad Institute Molecular Signatures Database v4.0 (<http://www.broadinstitute.org/gsea/msigdb/>). Gene sets with a false discovery rate p*-*value\<0.05 were considered significant. Genes that were up- or down-regulated were identified by selecting genes with logarithmic fold-change ratio (*PPARα^-/-^/PPARα^+^*^/+^) \> 1.3 (up-regulated genes) or \< −1.3 (down-regulated genes). The raw data have been deposited in NCBI Gene Expression Omnibus and made accessible through the GEO database (accession number: GSE39669 and GSE39670).

Cell sorting {#s4-8}
------------

E19.5 fetal hepatic cells were isolated as described above and incubated with PE- or FITC-conjugated monoclonal antibodies against DLK (LS-C179444) (LifeSpan Biosciences, Seatlle, WA) or CK18 (ab52459) (Abcam, Cambridge, MA) at 1:200 dilution in PBS supplemented with 0.1% fetal calf serum according to a protocol previously described ([@bib57]). The samples were then washed with PBS and mixed with 1 μg/ml propidium iodide before cell sorting using a FACSAria cell sorter (Becton Dickinson, San Jose, CA).

Flow cytometry {#s4-9}
--------------

Primary hepatocytes were isolated as described above. Mitochondria and peroxisomes were stained using MitoTracker Red and SelectFX Alexa Fluor 488 Peroxisome Labeling Kits (Life Technologies, Carlsbad, CA) according to the manufacturer's protocols. Negative controls without Mitotracker Red or fluorophore-conjugated secondary antibodies were used to gate the quadrants. Levels of mitochondrial membrane potential and intracellular ROS production were determined by tetramethylrhodamine, ethyl ester (TMRE) (ab113852) staining and 2',7' --dichlorofluorescin diacetate (DCFDA) (ab113851) (Abcam, Cambridge, MA) staining, respectively, according to the manufacturer's protocols. Treatments with carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP, an ionophore uncoupler of oxidative phosphorylation capable of eliminating mitochondrial membrane potential) at 20 μM for 10 min or N-acetylcysteine (NAC, an antioxidant) at 5 mM for 2 hr served as negative controls for the respective staining. A total of 10,000 events were recorded. The data were analyzed using BD FACSDiva software (version 6; Becton Dickinson, San Jose, CA) and further processed by FlowJo software (version 7.6.1; Tree Star, OR).

Measurement of Cellular ATP Production {#s4-10}
--------------------------------------

Primary hepatocytes were isolated and cultured as described above. Cellular ATP production was measured in the presence of 25 mM glucose, 10 mM galactose, or 2.5 μM rotenone (Sigma-Aldrich, Saint Louis, MO) using the ENLITEN ATP Assay System Bioluminescence Detection Kit (Promega, Madison, MI) according to the manufacturer's protocol. Bioluminescence signals were read on a GloMax 20/20 Luminometer (Promega, Madison, MI) and normalized to the total number of viable cells. Cell viability assay was performed in extracted primary hepatocytes using trypan blue exclusion test based on a protocol previously described ([@bib54]). The production of pyruvate via the glycolytic metabolism of glucose yields 2 net ATP, but the same catalytic pathway yields no net ATP when galactose is used instead of glucose, thereby forcing cells to rely on oxidative phosphorylation for energy. Thus, the use of galactose in the primary hepatocyte culture acts as a positive control for the measurement of oxidative phosphorylation-dependent energy production ([@bib1]).

Oxygen Consumption Rate (OCR) Measurement {#s4-11}
-----------------------------------------

Primary hepatocytes were isolated as described above and 2 × 10^4^ cells seeded per well on XF-24 cell culture plates (Seahorse Bioscience, Billerica, MA) coated with rat tail collagen in DMEM medium containing 5% FCS and incubated overnight at 37°C. The cellular oxygen consumption rate was measured as described previously ([@bib42]). The next day, cells were equilibrated with buffer (111 mM NaCl, 4.7 mM KCl, 2 mM MgSO~4~, 1.2 mM Na~2~HPO~4~, 2.5 mM glucose, 0.5 mM carnitine) and incubated at 37°C for 60 min. The basal cellular respiration was measured without any treatment for 15 min (n = 9 per group), followed by treatment with 200 μM palmitate conjugated with BSA in a 6:1 molar ratio or BSA alone for 40 min (n = 6 per group). To measure the mitochondrial fatty acid oxidation, cells were subsequently incubated with 300 μm etomoxir, a known carnitine palmitoyltransferase I inhibitor, for another 30 min (n = 3 per group). All measurements utilized the Seahorse XF24 Flux Analyzer (Seahorse Biosciences, Billerica, MA). The OCR of whole hepatocytes was standardized for total protein concentration after the assay was completed.

Histological analysis {#s4-12}
---------------------

Fresh liver samples were collected and embedded in OCT tissue freezing medium (Leica Microsystems, Wetzlar, Germany). Oil Red O stock solution was prepared by dissolving 0.5 g of Oil Red O powder (Sigma-Aldrich, St. Louis, MO) in 500 ml isopropanol. To constitute 50 ml of 60% Oil Red O working solution, 30 ml of the stock solution was diluted with 20 ml of water. Fresh-frozen samples were sectioned (6 μm thick) and stained with 60% Oil Red O solution for 10 min. The Oil Red O-stained sections were counterstained with methylene blue.

Analysis of serum and tissue metabolites {#s4-13}
----------------------------------------

Serum glucose and triglyceride levels were measured using the Accutrend Plus meter (Roche Diagnostics, Indianapolis, IN). Serum β-hydroxybutyrate and liver ALT levels were measured using the β-hydroxybutyrate Assay Kit and ALT Activity Assay Kit, respectively (Sigma-Aldrich, Saint Louis, MO). Lipids were extracted from the liver samples by the Bligh/Dyer method and analyzed by gas-liquid chromatography as previously described ([@bib65]).

High-fat-diet weaning challenge {#s4-14}
-------------------------------

Although feeding the P5 pups with milk harvested from *Ppara^+/-^ *dams would be ideal for this HFD-weaning challenge, we were ethically and technically restricted to perform oral gavage in these young pups and to collect sufficient milk for this experiment. For these reasons, we resorted to the best compromise by exposing the pups to a high-fat/low-carbohydrate (HF/LC) diet or a control diet from P5 (i.e., just before tooth eruption) to P15 (i.e., when liver steatosis is mostly resolved). The diets (Provimi Kliba, Kaiseraugst, Switzerland) had the following macronutrient compositions (% w/w: fat, carbohydrates, protein): control, 16.7/64.3/19.0 (\#2222) ([Table 4](#tbl4){ref-type="table"}) and HF/LC, 74.4/6.6/19.0 (\#2201) ([Table 5](#tbl5){ref-type="table"}). Both diets used identical macronutrient sources (fat source: beef tallow; carbohydrate source: starch; protein source: casein), allowing a precise comparison of differences in macronutrients.10.7554/eLife.11853.018Table 4.Control diet formulation.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.018](10.7554/eLife.11853.018)**Manufacturer**: KLIBA NAFAG, SWITZERLAND\
**Product ID**: 2222**Mouse and ratExperimental diet, purified dietAIN-93GMajor nutrients** Dry matter90.0%Crude protein18.0%Crude fat7.0%Crude fiber3.5%Crude ash3.0%Nitrogen-free extract (NFE)58.5%Gross energy17.5 MJ/kgMetabolic energy15.9 MJ/kgStarch35.0%**Amino acids** Arginine0.65%Lysine1.40%Methionine0.50%Methionine + cystine0.85%Tryptophan0.22%Threonine0.70%**Major mineral elements** Calcium0.52%Phosphorus0.32%Magnesium0.08%Sodium0.22%Potassium0.36%Chlorine0.15%**Trace elements** Iron65 mg/kgZinc45 mg/kgCopper6 mg/kgIodine0.6 mg/kgManganese12 mg/kgSelenium0.2 mg/kg**Vitamins** Vitamin A4000 IU/kgVitamin D~3~1000 IU/kgVitamin E100 mg/kgVitamin K~3~4 mg/kgVitamin B~1~6 mg/kgVitamin B~2~6 mg/kgVitamin B~6~7 mg/kgVitamin B~12~0.05 mg/kgNicotinic acid30 mg/kgPantothenic acid16 mg/kgFolic acid2 mg/kgBiotin0.2 mg/kgCholine1200 mg/kg**Ingredients** Corn starch, casein, dextrose, sucrose, refined soybean oil, cellulose, minerals, vitamins, amino acids **Remarks** - Experimental diet for mice and rats - Given values are calculated averages in air-dry feed - Production on demand **Delivery form** Pellets 10 mm round **2222.PH.A05:** 5 kg in welded aluminium bag\
**2222.MA.A05:**\
5 kg in welded aluminium bag KLIBA NAFAG \| PROVIMI KLIBA AG \| CH-4303 Kaiseraugst \| Tel. +41 61 816 16 16 \| Fax. +41 61 816 18 00 \|\
kliba-nafag\@provimi-kliba.ch \| [www.kliba-nafag.ch](http://www.kliba-nafag.ch)10.7554/eLife.11853.019Table 5.High-fat diet formulation.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.019](10.7554/eLife.11853.019)**Manufacturer**: KLIBA NAFAG, SWITZERLAND\
**Product ID**: 2201**Mouse and ratExperimental diet, purified dietKetogenic diet XL75:XP10Major nutrients**Dry matter99.1%Crude protein9.9%Crude fat74.4%Crude fiber5.5%Crude ash6.3%Nitrogen-free extract (NFE)3.0%Metabolic energy7208 kcal/kgStarch0.7%**Amino acids**Arginine0.35%Lysine0.79%Methionine0.28%Methionine + cystine0.90%Tryptophan0.13%Threonine0.38%**Major mineral elements**Calcium0.98%Phosphorus0.61%Magnesium0.15%Sodium0.40%Potassium0.69%Chlorine0.57%**Trace elements**Iron151 mg/kgZinc97 mg/kgCopper16 mg/kgIodine1.4 mg/kgManganese31 mg/kgSelenium0.6 mg/kg**Vitamins**Vitamin A8000 IU/kgVitamin D~3~2000 IU/kgVitamin E200 mg/kgVitamin K~3~9 mg/kgVitamin B~1~12 mg/kgVitamin B~2~13 mg/kgVitamin B~6~14 mg/kgVitamin B~12~0.1 mg/kgNicotinic acid66 mg/kgPantothenic acid32 mg/kgFolic acid5 mg/kgBiotin0.4 mg/kgCholine1975 mg/kg**Ingredients**Beef fat, casein, cellulose, minerals, vitamins, amino acids**Remarks**- Experimental diet for mice and rats- Given values are calculated averages in air-dry feed- Production on demand**Delivery form**Paste**2201.MA.A05:**5 kg in welded aluminium bagKLIBA NAFAG \| PROVIMI KLIBA AG \| CH-4303 Kaiseraugst \| Tel. +41 61 816 16 16 \| Fax. +41 61 816 18 00 \|\
kliba-nafag\@provimi-kliba.ch \| [www.kliba-nafag.ch](http://www.kliba-nafag.ch)

L-cycloserine treatment {#s4-15}
-----------------------

Two-day-old pups were injected with L-cycloserine (Sigma-Aldrich, Saint Louis, MO) at 30 mg/kg/day or 0.9% saline (vehicle control) for 2 to 4 days. Blood glucose and body weight of the pups was monitored before and after treatment.

Western blot analysis {#s4-16}
---------------------

Cytoplasmic and nuclear protein fractions were isolated as described above. For Western blotting, equal amounts of protein extracts (20 μg) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred onto a nitrocellulose membrane. The membranes were processed as recommended by the antibody suppliers. Chemiluminescence was detected using the Luminata Crescendo Western HRP Substrate (Millipore, MA). Beta-tubulin and U2AF65 were used to check for equal loading and the transfer of cytoplasmic and nuclear proteins, respectively. Primary antibody against full-length ANGPTL4 was a kind gift from Prof. Andrew Tan Nguan Soon. Primary antibodies against ACOX1 (\#sc-98499), FGF21(\#sc-292879), CYP4A14 (\#sc-46087), β-tubulin (\#sc-9104), U2AF65 (\#sc-48804), GR (\#sc-1004), and HDAC3 (\#sc-17795), and all secondary antibodies conjugated with horseradish peroxidase were acquired from Santa Cruz Biotechnology (Dallas, TX). PPARα polyclonal antibody (\#101710) was purchased from Cayman Chemical (Ann Arbor, MI).

Ex vivo tissue culture {#s4-17}
----------------------

Fetal livers (E19.5) were sliced \< 0.1-mm-thick using two adjacent scalpel blades and cultured on collagen-coated plates at 37°C for 24 hr in DMEM:F12 with 10% fetal bovine serum containing 5 mM butyrate, 5 mM β-hydroxybutyrate, or 0.3 μM trichostatin A. All of these chemicals were acquired from Sigma-Aldrich (Saint Louis, MO).

statistical analysis {#s4-18}
--------------------

We performed power analysis for sample size estimation using Power And Precision software (version 4) by Biostat Inc. when the study was being designed. We set the mean outcome for *Ppara^+/+^* and *Ppara^-/-^* mice at 100 and 80, respectively (i.e., 20% difference) and estimated the standard deviation to be ± 10% based on our preliminary data. We estimated that a total of 6 mice per group is needed in order to have a power of 80%, which means there is an 80% likelihood that the study will yield a statistically significant (i.e., α value = 0.05) effect to allow us to detect a mean outcome difference of 20% between *Ppara^+/^*^+^ and *Ppara*^-/-^ mice. The outcomes (e.g., gene expression, metabolic parameters) are measured on a continuous scale. The null hypothesis is that the mean outcome for these two groups is identical. The computation of the sample size is based on the assumption that there would be no missing data (i.e., all mice will produce data). The data in all figure panels reflect multiple experiments performed on different days using pups (n = 6 with triplicates) derived from different litters. In this study, we used 6 mice per group (i.e., biological replicates) for all experiments. Further, measurements and experiments were repeated in triplicates for each sample (i.e., technical replication). Values were expressed as mean ± standard error of the mean (SEM). Statistical tests, including the two-tailed Mann-Whitney and two-way ANOVA with Bonferroni post-hoc analysis, were performed using GraphPad Prism software (version 5.00). p*-*values\<0.05 were considered significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Prenatal glucocorticoid signaling is required for PPARα activity and epigenetic regulation of FGF21 at birth\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by K VijayRaghavan as the Senior Editor who also served as Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Sander Kersten (peer reviewer).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this paper Rando, G et al. elegantly show a new mechanism by which PPARα controls hepatic adaptation to changes in the nutrition during the late stages of development and at birth. The story is very interesting as general knowledge and it adds a novel model by which the liver may adapt to changes in the diet and how this adaptation could be exploited in health and disease. Specifically, the paper explores the mechanism underlying the activation of the transcription factor PPARα in liver during the late embryonic period and the impact of this mechanism on cellular energetics and lipid metabolism. The paper highlights the crucial role of the glucocorticoid receptor in activation of PPARα during embryogenesis, and proposes a contribution of epigenetic mechanisms involving the ketone body β-hydroxybutyrate. The paper consists of a number of mini-stories that differ substantially in the quality of the data and in the level of depth provided. Some of the mini-stories are mostly confirmatory, while others are novel. The unification of the individual stories into a coherent and convincing overall message is a bit problematic and deserves attention. Even though the experiments are very well conducted, there are some pitfalls that should be resolved for a better understanding of the main points of the story.

The finding that PPARα target genes exhibit different types of expression profiles pre- and post-natally is worthy of a more detailed mechanistic pursuit. The demonstration that the glucocorticoid receptor is the driving force behind induction of PPARα during embryogenesis and directly binds to the PPARα promoter is very interesting and novel. The data showing a major impact of PPARα deletion on neonatal lipid metabolism are confirmatory of a publication by Cotter et al. (Am J Physiol Endocrinol Metab. 2014 Jul 15; 307(2): E176-E187). The data on epigenetic regulation of PPARα target genes are interesting but do not link particularly well to the data on lipid metabolism. Β-hydroxybutyrate may contribute to induction of specific PPARα target genes (*Fgf21*) via epigenetic mechanism but how does this effect connect to the observed phenotype of *Ppara^-/-^* mice. The part describing epigenetic regulation by β-hydroxybutyrate is potentially very exciting (following the work of Verdin) but the physiological/metabolic rationale needs to be better explained.

Overall, the paper has quite a few rough edges. The presentation/description of the data and story lines can be much improved. The paper would benefit from a more linear story line from GR to PPARα to ketone bodies to epigenetic regulation of *Fgf21* (while perhaps mentioning a potential vicious cycle between PPARα, ketone bodies and *Fgf21*). Some figures should be removed as they are unnecessary and distracting (confirmatory data of Cotter, data on gluconeogenesis and anaplerotic oxidation of amino acids). It would be fantastic if the role of β-hydroxybutyrate in epigenetic gene regulation of *Fgf21* could be confirmed via in vivo data but that would be an unreasonable request.

All three reviewers mention that the storyline of the paper is complex and that the structure of the paper needs to be substantially improved. That is something that could be completed in two months. As far as additional analyses are concerned, the possible translation of the data to humans should addressed with more caution and in any case be very difficult to address experimentally. We would appreciate additional elaboration on the generalizability of effect of β-hydroxybutyrate on gene expression. The authors are encouraged to look at additional genes to solidify this very interesting finding.

Essential revisions:

We list the major comments from each reviewer rather than consolidating them. They are largely distinct with some overlap.

Reviewer 1:

1\) It is described that PPARα null and WT animals were maintained on a mixed C57BL/6 × SV129 background and bred by intercrossing mice heterozygous for the mutation. The rationale for this practice is unclear. First, PPARα null mice are available at Jackson labs on a pure C57BL/6 or SV129 background, which would be preferred over a mixed genetic background. In addition, PPARα null mice are perfectly viable as homozygous. Why weren\'t PPARα null maintained as homozygous and compared with wildtype mice matched for genetic background?

2\) For [Figure 1B](#fig1){ref-type="fig"} to be meaningful, the entire set of PPARα targets within a metabolic pathway should be shown (as opposed to a potentially biased subselection of genes) or the comparative analysis should be performed statistically at the pathway level.

3\) In the second paragraph of the Results section: the nearly 90% reduction in ATP production in *Ppara^-/-^*hepatocytes as compared to WT hepatocytes seems implausible, especially considering that the cells were fed with glucose or galactose. Could it be that these results are reflective of the low viability of the *Ppara^-/-^* hepatocytes? There is no mentioning of measurement of cell viability in the primary hepatocytes.

4\) Please explain why palmitate and etomoxir do not have any influence on oxygen consumption in either *Ppara*^+/+^ or *Ppara^-/-^* hepatocytes. The lack of effect of etomoxir on oxygen consumption in *Ppara*^+/+^ hepatocytes suggests that the difference in oxygen consumption between *Ppara*^+/+^ and *Ppara^-/-^*hepatocytes is not related to differences in fatty acid oxidation.

5\) The part of the manuscript addressing plasma glucose (subsection "PPARα Required for Protection against Neonatal Hepatic Steatosis", last paragraph) is poorly developed. It is unclear why a *lack* of difference in plasma glucose levels or body weight between the two genotypes would prompt the authors to check whether the gluconeogenesis pathway is modified.

6\) It is described that \"... increased anaplerotic oxidation of amino acids may be an alternative pathway for maintaining the de novo synthesis of glucose as an energy source when the FAO capacity is impeded in the absence of PPARα\". What is the evidence that oxidation of amino acids may be increased? The genes shown in Figure 3---figure supplement 2E are part of an energy-requiring process: gluconeogenesis.

7\) In the Discussion section, increased anaplerotic oxidation of amino acids is proposed as a potential explanation for the discrepancy with Cotter et al., who found that *Ppara^-/-^* pups were hypoglycemic. Why would anaplerotic oxidation of amino acids be different between the two studies?

8\) The interpretation of the experiment with L-cycloserine is difficult. Did the authors verify that it effectively inhibited gluconeogenesis? For instance, were plasma glucose levels altered. The authors don\'t derive any conclusion from this experiment. Why was it included?

9\) In the last paragraph of the Results section: Rephrase \"Activation of the *Fgf21* TSS and the levels of *Fgf21* mRNA required both the activation of PPARα by Wy and HDAC3 inhibition through butyrate or β-hydroxybutyrate treatment.\" Can the authors explain why WY has no effect on *Fgf21* mRNA or transcriptional activation in the absence of butyrate of β-hydroxybutyrate ([Figure 7A](#fig7){ref-type="fig"}), whereas WY alone effectively induces polII binding to the *Fgf21* TSS in [Figure 5E](#fig5){ref-type="fig"}.

Reviewer 2:

1\) Hepatocytes from E14.5 and E15.5 did not show any changes in the activity of *Pparα*, which is not surprising since at this stage of liver development the liver bud generates mainly hematopoietic cells and precursors. At later stages we can expect that some hepatic precursors appear and at 19.5 there is a mixed population of cells in the liver: one compartment is the undifferentiated hepatoblasts and the other is the newly formed hepatocytes. Since the deletion of *Pparα* is constitutive, it would be important to show if either the changes seen at E19.5 are stemming from the pluripotent hepatoblasts compartment or from the hepatocytes. The same is observed in the newly born population. This is a key point to be addressed since it could change the main story. It is expected that hepatoblasts will show an aerobic glycolytic metabolic profile, as seen in many other stem cell-like population; but it would be important to address what happens to hepatocytes before birth?

2\) In the *Ppara^-/-^*mice there are many changes but the most relevant one is related to the number of mitochondria. How can it be excluded that all the changes in FAO and gluconeogenesis observed are not cellular-autonomous metabolic adaptation as a result of the lower number of mitochondria instead of epigenetic regulation? Is the mitochondrial potential maintained in these mitochondria? What is the redox status of the mitochondria and the cytoplasm? Can it be excluded that the induction of β-Hydroxybutyrate is not due to mitochondrial defects?

3\) Related to the previous question, the authors claim that ALT could be activated to replenish the TCA cycle in the absence of *Pparα*. This is very interesting, but not backed up by solid data. The ALT activity is mainly cytoplasmic because the liver expresses mainly the cytoplasmic isoform of Gpt (ALT). Therefore, if the reactions occur in the cytoplasm, it is expected to be accompanied by changes in the mitochondrial potential. This would need to be shown. In some cases, the change in the pyruvate flux to alanine will affect amino acid metabolism. Were any changes in the expression of genes from amino acid metabolism detected in the microarray data? In addition, is there a reason that ALT would be more active?

4\) For the ChIP-seq data, the authors should show that the antibody against GR does not pull down anything in the *GR*^-/-^ livers.

5\) The paper is written in a complicated fashion, which makes understanding of the most important points tedious. The authors should be encouraged to simplify their writing.

Reviewer 3:

1\) The mice used are classical PPARα k.o. mice. How specific are the effects found for the liver (in particular in vivo) as the PPARα is expressed in many organs (including the gut) and this could influence the outcome?

2\) The hepatic steatosis in *Ppara^-/-^* is caused by? The dietary fat or more related to the carb part of the diet leading to de novo lipogenesis that is also under control of PPARα, I thought (references are not mentioned describing the role in regulating \'new\' fat metabolism). Translated to the human situation early breastmilk has a rather low fat content and as a baby breastfeeds, the fat content very gradually increases, with the milk becoming fattier and fattier over time. So in the beginning is largely a sweet high lactose/carb feed; how does this relate to this study?

3\) Related to this the HF diets used for the challenge are quite extreme, ketogenic diets, why this is needed as I guess this is not the same in the human situation? I do not see the full relevance for this challenge? To induce FGF21? Is FGF21 functional for early nutrition related metabolic regulation or more related to starvation/low calorie periods of the baby (where β-hydroxybutyrate also goes up?), so is it ketogenesis because of ketogenic diets or fasting-related metabolic states? I am not really convinced of the diets used here to mimic (human) milk. Human milk is clearly not a ketogenic diet. So I question the regulation of FGF21 because of the milk.

4\) The composition is not precisely mentioned e.g. no lactose or sucrose in the diet?). On the other hand, using chow is not ideal as it will prevent the exact reproducibility of this study because of the natural/variable ingredients of the chow.

In summary, I am not so convinced yet that the main finding of this paper (epigenetic regulation of FGF21, which has been partly described before, and partly attributed to SIRT1/3) is really related to the HF diet challenge but it could be also alternatively explained as it might contribute in the difficult periods of low-/no-food /starvation when bHB is providing fuel for the brain to optimize glucose transport by other organs to prevent hypoglycemia etc.?

10.7554/eLife.11853.026

Author response

Summary:

\[...\] All three reviewers mention that the storyline of the paper is complex and that the structure of the paper needs to be substantially improved. That is something that could be completed in two months. As far as additional analyses are concerned, the possible translation of the data to humans should addressed with more caution and in any case be very difficult to address experimentally. We would appreciate additional elaboration on the generalizability of effect of β-hydroxybutyrate on gene expression. The authors are encouraged to look at additional genes to solidify this very interesting finding.

Thank you for this comprehensive summary, which highlights the strengths and weaknesses of our manuscript. We have addressed all the reviewers' comments in the following point-by-point response.

In response to some of the comments highlighted in this summary but not raised by the reviewers, we have made the following changes in the manuscript:

We have changed the title of the manuscript to "Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism" to better encapsulate the major findings reported in our revised manuscript.

We have reconstructed the manuscript to streamline the story (from GR to PPARα to ketone bodies to epigenetic regulation of *Fgf21*) and simplified our writing to enhance accessibility to a broad readership. We have also discussed and placed more emphasis on the physiological relevance of our work in the Discussion.

We have now established the connection between epigenetic regulation of PPARα target genes (particularly FGF21) and lipid metabolism in the Discussion (sixth paragraph). In particular, the physiological/metabolic relevance of the epigenetic regulation of FGF21 by β-hydroxybutyrate has been discussed.

We have also established the connection between the induction of FGF21 via HDAC3 inhibition by β-hydroxybutyrate and the observed phenotype of *Ppara^-/-^*mice in the Discussion (sixth paragraph).

We did not remove some of the figures as suggested (e.g., gluconeogenesis and anaplerotic oxidation of amino acids) because we believe that these data complement the work of Cotter et al. and provide important information on the overall metabolic situations in the absence of PPARα. We believe that you found the inclusion of these data unnecessary and distracting because of our failure to successfully integrate/connect this information with other parts of the metabolic processes. We have tried to address this shortfall in the Discussion of the revised manuscript (fourth paragraph).

We have mentioned, as suggested, a potential vicious cycle between PPARα, ketone bodies and FGF21 in the Discussion (last paragraph). We have also constructed a schematic illustration of this vicious cycle ([Figure 8C](#fig8){ref-type="fig"}).

Due to time constraint for resubmission, we did not validate the role of β-hydroxybutyrate in epigenetic regulation of *Fgf21* in vivo. However, we have further discussed the work by Verdin and coworkers (Shimazu et al., 2013) (PMID: 23223453) in which β-hydroxybutyrate was identified in vivo as the endogenous HDAC inhibitor (Discussion, fifth paragraph).

We have addressed the possible translation of the data to human situations in the Discussion with more caution (sixth paragraph).

We have included additional data on another PPARα regulated gene, *Angptl4*, which like *Fgf21* functions as an adaptive regulator of metabolism whose expression is also governed by the β-hydroxybutyrate-mediated HDAC3 inhibition. The new data can be found in [Figure 6E](#fig6){ref-type="fig"}. It is important to note that, unlike *Fgf21*, the expression of *Angptl4* started before birth. We have reported this new data in the Results (subsection "An Epigenetic Switch Controls a Subset of PPARα Target Genes", last paragraph) and further discussed this difference in the Discussion (sixth paragraph).

Further, we have also performed several additional experiments and we believe that the new data have strengthened our work. We hope that the revised version of the manuscript will meet your expectations. Thank you very much for your consideration and the constructive comments that have helped us improve our manuscript.

Essential revisions:

*We list the major comments from each reviewer rather than consolidating them. They are largely distinct with some overlap.*

Reviewer 1:

1\) It is described that PPARα null and WT animals were maintained on a mixed C57BL/6 × SV129 background and bred by intercrossing mice heterozygous for the mutation. The rationale for this practice is unclear. First, PPARα null mice are available at Jackson labs on a pure C57BL/6 or SV129 background, which would be preferred over a mixed genetic background. In addition, PPARα null mice are perfectly viable as homozygous. Why weren\'t PPARα null maintained as homozygous and compared with wildtype mice matched for genetic background?

We thank the reviewer for bringing to our attention this lack of clarity in the rationale of our breeding strategy. In addition, this good comment made us realize that there was a mistake in our text.

Firstly, we acquired PPARα-knockout (*Ppara^-/-^*) mice on a pure C57BL/6 background from the Jackson Laboratory and inter-crossed them with our in-house wild-type (WT) C57BL/6 mice for at least 5 generations to generate PPARα-heterozygous (HT) mice. We have corrected this information in the Materials and methods (first paragraph).

Secondly, we obtained the foetuses and pups through heterozygous mating so that we could control for gestational and lactational confounding factors introduced by using dams from different genotypes (WT and *Ppara^-/-^*). It is currently unknown whether PPARα deficiency in lactating dams can lead to alteration in milk composition, as it is the case for PPARγ-knockout mice (Wan et al., 2007) (PMID: 17652179). Therefore, it was important to ensure that both WT and *Ppara^-/-^*pups received milk of the same nutritional content from the HT dams. We have clarified this rationale in the Materials and methods (subsection "ChIP Assays").

2\) For [Figure 1B](#fig1){ref-type="fig"} to be meaningful, the entire set of PPARα targets within a metabolic pathway should be shown (as opposed to a potentially biased subselection of genes) or the comparative analysis should be performed statistically at the pathway level.

We have performed an unbiased comparative analysis of the similarly and differentially regulated (both up- and down-regulation) genes between WT and *Ppara^-/-^*foetuses at E19.5 and pups P2. Statistical analysis was also performed with *p-*values indicated for the top 10 most affected pathways for each category. This piece of information can be found in [Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}).

3\) In the second paragraph of the Results section: the nearly 90% reduction in ATP production in Ppara^-/-^ hepatocytes as compared to WT hepatocytes seems implausible, especially considering that the cells were fed with glucose or galactose. Could it be that these results are reflective of the low viability of the Ppara^-/-^ hepatocytes? There is no mentioning of measurement of cell viability in the primary hepatocytes.

We thank the reviewer for this comment. As suggested, we have repeated the ATP measurements using primary hepatocytes obtained from E19.5 and P2 livers (n=4 per time point per group). We have performed trypan blue exclusion test to quantify the number and percentage of viable cells. We observed a \~20% reduction in the number of viable primary *Ppara^-/-^*hepatocytes as compared with the WT hepatocytes at both time points, despite that these two groups were simultaneously extracted using the same procedure (see [Author response image 1](#fig9){ref-type="fig"}, left panel). We subsequently normalized ATP production to the number of viable cells and found that ATP production in *Ppara^-/-^*hepatocytes was \~40-50% of the levels measured in both prenatal and postnatal WT controls ([Figure 3E](#fig3){ref-type="fig"} or [Author response image 1](#fig9){ref-type="fig"}, right panel). We have reported the new data in the Results (subsection "PPARα Controls the Prenatal Lipid Catabolic Machiner", last paragraph).

and Ppara^-/-^ hepatocytes is not related to differences in fatty acid oxidation.10.7554/eLife.11853.020Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.11853.020](10.7554/eLife.11853.020)

*4) Please explain why palmitate and etomoxir do not have any influence on oxygen consumption in either Ppara*^+/+^ *or Ppara^-/-^ hepatocytes. The lack of effect of etomoxir on oxygen consumption in Ppara*^+/+^ *hepatocytes suggests that the difference in oxygen consumption between Ppara*^+/+^*and Ppara^-/-^ hepatocytes is notrelated to differences in fatty acid oxidation.*

We apologise for the confusion caused as we previously did not indicate the statistical significance between the treatment groups of the same genotype. We have now performed two-tailed Mann-Whitney *U* test for these observed differences in palmitate treatment groups (where ^\#\#\#^ indicates *P* \< 0.001 vs. baseline), and in palmitate + etomoxir treatment groups (where ^§§§^ indicates *P* \< 0.001 vs. palmitate treatment alone). We found that the differences were statistically significant in WT but not in *Ppara^-/-^* groups. To clarify this, we have included the indications of significance in [Figure 3G](#fig3){ref-type="fig"}.

5\) The part of the manuscript addressing plasma glucose (subsection "PPARα Required for Protection against Neonatal Hepatic Steatosis", last paragraph) is poorly developed. It is unclear why a lack of difference in plasma glucose levels or body weight between the two genotypes would prompt the authors to check whether the gluconeogenesis pathway is modified.

We thank the reviewer for highlighting this lack of clarity in the rationale of investigating the gluconeogenesis pathway. It is known that the transition from a carbohydrate-rich fetal diet to a high-fat, low-carbohydrate neonatal diet requires inductions of hepatic fatty acid oxidation (FAO), gluconeogenesis, and ketogenesis in order to preserve bioenergetics homeostasis (Cotter et al., 2013) (PMID: 23689508). In addition, an effective hepatic FAO is necessary to support hepatic de novo ketogenesis and gluconeogenesis by providing essential co-factors such as acetyl-CoA and/or NADH (Girard, 1986) (PMID: 3542066). Since PPARα deficiency leads to defective hepatic FAO and hypoketonemia, we were interested to find out whether the gluconeogenesis pathway is altered to sustain the energy demand for normal growth. We have clarified this point in the Results (subsection "PPARα Is Required for Protection against Neonatal Hepatic Steatosis", last paragraph).

6\) It is described that \"... increased anaplerotic oxidation of amino acids may be an alternative pathway for maintaining the de novo synthesis of glucose as an energy source when the FAO capacity is impeded in the absence of PPARα\". What is the evidence that oxidation of amino acids may be increased? The genes shown in Figure 3---figure supplement 2E are part of an energy-requiring process: gluconeogenesis.

Based on our microarray data, we have delineated that most of genes coding for the rate-limiting enzymes involved in amino acid oxidation were concomitantly up-regulated in the *Ppara^-/-^* liver at P2 (except for valine, leucine, and isoleucine). Up-regulation of these genes provides some of the intermediate substrates in TCA/Krebs cycle, such as α-ketoglutarate, fumarate, and oxaloacetate, which are ultimately used for gluconeogenesis. We have incorporated this information in the Results (subsection "PPARα Is Required for Protection against Neonatal Hepatic Steatosis", last paragraph) and in [Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"} with the gene name indicated in the figure legend.

7\) In the Discussion section, increased anaplerotic oxidation of amino acids is proposed as a potential explanation for the discrepancy with Cotter et al., who found that Ppara^-/-^ pups were hypoglycemic. Why would anaplerotic oxidation of amino acids be different between the two studies?

We thank the reviewer for highlighting this point. The hypoglycemic phenotype was reported by Cotter et al. in *Ppara^-/-^* pups at P1 due to a decreased hepatic production of glucose from glycerol. However, we did not detect any sign of hypoglycemia in *Ppara^-/-^*neonates starting from P2. We believe the findings from the two groups complement each other. This apparent discrepancy is likely attributable to the rapid (\~ 1 day) and dynamic adaptive function of the neonatal liver in maintaining glucose homeostasis via anaplerotic amino acid oxidation, which was particularly evident in the *Ppara^-/-^* liver at P2. We have further discussed this discrepancy and emphasized on this implication in the Discussion (fourth paragraph).

8\) The interpretation of the experiment with L-cycloserine is difficult. Did the authors verify that it effectively inhibited gluconeogenesis? For instance, were plasma glucose levels altered. The authors don\'t derive any conclusion from this experiment. Why was it included?

We thank the reviewer for the comment. We have now measured the plasma glucose levels in WT and *Ppara^-/-^* pups after L-cycloserine treatment. We found that L-cycloserine treatment consistently impeded the production of glucose in *Ppara^-/-^* pups at P2, P4, P5 and P6. This finding further supports the notion that anaplerotic amino acid oxidation in *Ppara^-/-^* liver provides the intermediate substrates in TCA/Krebs cycle required for the gluconeogenesis pathway ([Figure 4---figure supplement 2D and E](#fig4s2){ref-type="fig"}). We have included this information in the Results (subsection "PPARα Is Required for Protection against Neonatal Hepatic Steatosis", last paragraph) and in [Figure 4---figure supplement 2G](#fig4s2){ref-type="fig"}.

9\) In the last paragraph of the Results section: Rephrase \"Activation of the Fgf21 TSS and the levels of Fgf21 mRNA required both the activation of PPARα by Wy and HDAC3 inhibition through butyrate or β-hydroxybutyrate treatment.\" Can the authors explain why WY has no effect on Fgf21 mRNA or transcriptional activation in the absence of butyrate of β-hydroxybutyrate ([Figure 7A](#fig7){ref-type="fig"}), whereas WY alone effectively induces polII binding to the Fgf21 TSS in [Figure 5E](#fig5){ref-type="fig"}.

We thank the reviewer for highlighting this interesting point. It was previously indicated that HDAC-mediated histone deacetylation may inhibit transcription at the initiation and/or elongation step (Wang et al., 2009) (PMCID: PMC2750862). If the genes are loaded by Pol2 at the TSS, similar to what we observed at the *Fgf21* TSS upon PPARα agonistic activation, HDAC-mediated inhibition of transcription most likely happens at the elongation step although abortive initiation by the TSS bound Pol2 cannot be excluded. Our results suggest that PPARα activation induces the recruitment and assembly of transcription initiation complex at the *Fgf21* TSS. However, the elongation of *Fgf21* mRNA transcript only ensues after alleviation of HDAC3 inhibition by β-hydroxybutyrate. Therefore, it is consistent with our findings that WY-14643 has no effect on *Fgf21* mRNA or transcriptional activation in the absence of butyrate or β-hydroxybutyrate due to HDAC3-mediated inhibition. We have discussed this in the Discussion (fifth paragraph).

We have also rephrased the sentence (Results), which now reads "Activation of the *Fgf21* transcriptional activity was dependent on both the activation of PPARα and HDAC3 inhibition through butyrate or β-hydroxybutyrate treatment".

Reviewer 2:

1\) Hepatocytes from E14.5 and E15.5 did not show any changes in the activity of Pparα, which is not surprising since at this stage of liver development the liver bud generates mainly hematopoietic cells and precursors. At later stages we can expect that some hepatic precursors appear and at 19.5 there is a mixed population of cells in the liver: one compartment is the undifferentiated hepatoblasts and the other is the newly formed hepatocytes. Since the deletion of Pparα is constitutive, it would be important to show if either the changes seen at E19.5 are stemming from the pluripotent hepatoblasts compartment or from the hepatocytes. The same is observed in the newly born population. This is a key point to be addressed since it could change the main story. It is expected that hepatoblasts will show an aerobic glycolytic metabolic profile, as seen in many other stem cell-like population; but it would be important to address what happens to hepatocytes before birth?

We thank the reviewer for the suggestions. Since there is a heterogeneous population of undifferentiated hepatoblasts and differentiated hepatocytes in the liver at E19.5, we determined whether hepatoblasts and/or hepatocytes were responsible for the observed changes in mRNA expression. Using antibodies against hepatoblast- and hepatocyte-specific marker (i.e., DLK and CK18, respectively), we performed flow cytometric analyses on the cells extracted from *Ppara*^+/+^ and *Ppara^-/-^* livers at E19.5. Upon cell sorting, we specifically recovered the DLK^+^ and CK18^+^ fractions. We showed that PPARα deficiency only led to marginal changes in the abundance of these two hepatic cell populations ([Figure 2D](#fig2){ref-type="fig"}). Furthermore, we determined the mRNA expression of *GR, PPARα* and PPARα target genes in these cells. Our results indicated that both *Ppara*^+/+^ hepatoblasts and hepatocytes similarly contributed to the expression of these genes ([Figure 2E](#fig2){ref-type="fig"}). Notably, we observed a modest but not significant upward trend in the expression of oxidative genes (e.g., *Acox1, Acaa2, Acadl*, and *Acadvl*) and a downward trend in the expression of glycolytic genes (e.g., *Gck* and *Hk1*) in the *Ppara*^+/+^ hepatocytes compared to hepatoblasts, thereby suggestive of a more pronounced oxidative program in these cells ([Figure 2E](#fig2){ref-type="fig"}). In contrast, the expression of these genes was concomitantly down-regulated in *Ppara^-/-^* hepatoblasts and hepatocytes, thereby highlighting the pivotal role of PPARα in glycolytic and oxidative metabolism in both cell types. We have reported this new data in the Results (subsection "PPARα Controls the Prenatal Lipid Catabolic Machinery", second paragraph).

2\) In the Ppara^-/-^mice there are many changes but the most relevant one is related to the number of mitochondria. How can it be excluded that all the changes in FAO and gluconeogenesis observed are not cellular-autonomous metabolic adaptation as a result of the lower number of mitochondria instead of epigenetic regulation? Is the mitochondrial potential maintained in these mitochondria? What is the redox status of the mitochondria and the cytoplasm? Can it be excluded that the induction of β-Hydroxybutyrate is not due to mitochondrial defects?

We thank the reviewer for raising this important point. Firstly, many of the PPARα regulated genes involved in FAO have previously been shown to contain PPRE in their promoter region and hence, recognized as direct PPARα target genes (Rakhshandehroo et al., 2010) (PMID: 20936127). This implicates that the reduced oxidative capacity observed in *Ppara^-/-^* mice was due to the lack of direct PPARα-mediated stimulatory effects rather than cellular-autonomous metabolic adaptation in response to lower mitochondria numbers.

Hepatic FAO has previously been shown to increase the gluconeogenic flux by providing acetyl-CoA and NADH which are both necessary for gluconeogenesis (Ferré et al., 1979) (PMID: 508300). This notion is in line with the observation of hypoglycemia in *Ppara^-/-^* pups at P1 (Cotter et al., 2014) (PMID: 24865983). However, we observed normoglycemia in these pups beyond P2. We subsequently delineated that a cell-autonomous adaptation enhanced in the absence of PPARα and mediated through up-regulation of alanine aminotransferase (ALT) and anaplerotic oxidation of amino acid oxidation (as shown in [Figure 4---figure supplement 2D and E](#fig4s2){ref-type="fig"}) was in place to maintain glucose homeostasis so as to sustain normal postnatal growth in *Ppara^-/-^* neonates. Thus, glucose became the primarily source of energy in these mice since they exhibited defective hepatic FAO and ketogenesis. In parallel, we also observed an augmented expression of pyruvate carboxylase (*Pcx)* and other gluconeogenic genes in *Ppara^-/-^* liver ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). This compensatory effect likely corresponds with a lower hepatic acetyl-CoA level, as supported by a recent report that the hepatic acetyl-CoA acts as an allosteric regulator of Pcx (Perry et al., 2015) (PMID: 25662011). We have discussed this information in the Discussion (fourth paragraph).

We have also measured mitochondrial membrane potential (∆Ψm) and intracellular ROS production levels, which are two common parameters used in assessing mitochondria health and functions (Suski et al., 2012) (PMID: 22057568). Interestingly, we observed a much lower mitochondrial membrane potential (∆Ψm) and a markedly increased intracellular ROS level in *Ppara^-/-^* hepatocytes at P2, indicative of mitochondria dysfunction at this stage ([Figure 3C,D](#fig3){ref-type="fig"}). However, there was no discernible difference in ∆Ψm between *Pparα*^+/+^ and *Ppara^-/-^* hepatocytes at E19.5 despite that a slight increase in the intracellular ROS level was observed in the latter. These findings suggest that an increased ROS level in cells likely precedes the loss of ∆Ψm and mitochondria dysfunction. This is consistent with a previous report of a similar mitochondrial disorder associated with the dysfunctions of the respiratory chain components (Lebiedzinska et al., 2010) (PMID: 20226758). Particularly, the increased intracellular ROS levels observed in *Ppara^-/-^* hepatocytes may be due to the reduced clearance of ROS as evidenced by the down-regulated of genes coding for mitochondrial superoxide dismutase 2 (SOD2) and copper chaperone for SOD1 before and/or after birth ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). Particularly, the increased intracellular ROS levels observed in *Ppara^-/-^* hepatocytes may be due to the reduced clearance of ROS as evidenced by the down-regulated of genes coding for mitochondrial superoxide dismutase 2 (SOD2) and copper chaperone for SOD1 before and/or after birth ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). This observation is consistent with the report that PPARα activation by agonist clofibrate stimulates SOD1 and catalase activities as part of the defence mechanism against oxidative stress in the heart (Ibarra-Lara et al., 2016). We have reported and discussed the new data in the Results (subsection "PPARα Controls the Prenatal Lipid Catabolic Machinery", last paragraph) and Discussion (third paragraph), respectively.

Lastly, the observed reduction in the serum β-hydroxybutyrate in *Ppara^-/-^* neonates is likely due to defective mitochondrial FAO, which provides the co-factors (e.g., acetyl-CoA and NADH) required for ketogenesis. We have discussed about this point in the Discussion (fourth paragraph).

3\) Related to the previous question, the authors claim that ALT could be activated to replenish the TCA cycle in the absence of Pparα. This is very interesting, but not backed up by solid data. The ALT activity is mainly cytoplasmic because the liver expresses mainly the cytoplasmic isoform of Gpt (ALT). Therefore, if the reactions occur in the cytoplasm, it is expected to be accompanied by changes in the mitochondrial potential. This would need to be shown. In some cases, the change in the pyruvate flux to alanine will affect amino acid metabolism. Were any changes in the expression of genes from amino acid metabolism detected in the microarray data? In addition, is there a reason that ALT would be more active?

In agreement with this interesting point raised by the reviewer, most of genes coding for the rate-limiting enzymes involved in amino acid oxidation were concomitantly up-regulated in *Ppara^-/-^* liver at P2 (except for valine, leucine, and isoleucine). Up-regulation of these genes provides some of the substrates in TCA cycle, such as α-ketoglutarate, fumarate, and oxaloacetate, which are ultimately used for gluconeogenesis. We have now incorporated this important information in [Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"}. We have also included the gene name of the rate-limiting enzymes involved in the pathways indicated in the figure legend. Thus far, we couldn't explain the increased *ALT* expression in *Ppara^-/-^* liver except that it involved a pathway up-regulated in the absence of PPARα to compensate for the defective FAO and hypoglycemia. Interestingly, the expression of *ALT2* has previously been shown to be up-regulated under metabolic stress (Salgado et al., 2014, PMID: 24418603). Furthermore, plasma and tissue ALT levels are elevated in response to endoplasmic reticulum (ER) stress (Josekutty et al., 2013) (PMID: 23532846). Interestingly, defective PPARα signaling has been reported to cause hepatic mitochondrial and ER stress in the pathogenesis of hepatic steatosis through reduced mRNA expression of the sarco/endoplasmic reticulum calcium ATPase (SERCA) (Su et al., 2014) (PMID: 24735884). Our microarray data revealed a consistent reduction by \~1.2-fold in the expression of *Atp2a2*, which encodes for SERCA, in *Ppara^-/-^* liver at E19.5 and P2, respectively ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}). We have incorporated this information in the Results (subsection "PPARα Is Required for Protection against Neonatal Hepatic Steatosis", last paragraph) and in the Discussion (fourth paragraph).

4\) For the ChIP-seq data, the authors should show that the antibody against GR does not pull down anything in the GR^-/-^ livers.

We thank the reviewer for the suggestion of this important control. Due to logistic limitation, we were unable to acquire *GR^-/-^*livers to meet the timeline for resubmission. Nonetheless, we have performed siRNA-mediated knockdown of GR in primary hepatocytes extracted from E17 *Pparα^+/+^*livers. Upon treatment with GR-targeting siRNA, the occupancy of GR at the -1007 to -993 GRE was significantly decreased as compared to treatment with non-targeting siRNA, thereby indicating the specificity of GR binding to this GRE ([Figure 1H](#fig1){ref-type="fig"}). We have reported this new data in Results (subsection "GR Controls PPARα Expression in the Late Fetus", last paragraph).

5\) The paper is written in a complicated fashion, which makes understanding of the most important points tedious. The authors should be encouraged to simplify their writing.

We thank the reviewer for the suggestion. We have reconstructed the manuscript to streamline the story and simplified our writing to enhance accessibility to a broader readership. We believe that the revised manuscript has now been improved to achieve these aims.

Reviewer 3:

1\) The mice used are classical PPARα k.o. mice. How specific are the effects foundfor the liver (in particular in vivo) as the PPARα is expressed in many organs(including the gut) and this could influence the outcome?

We agree with the reviewer on this point. PPARα is expressed in many organs including the intestine which is highly challenged in the perinatal life. To further support our findings, we have performed Oil-Red-O staining and histological examination on the livers of hepatocyte-specific *Ppara^-/-^* mice (*Ppara^fl/fl^Alb^Cre/+^*) and their wild-type littermates (*Ppara^fl/fl^*) ([Figure 4---figure supplement 1I](#fig4s1){ref-type="fig"}). We demonstrated that *Pparα^hep^*^-/-^ mice exhibited liver steatosis at P3. Hence, we conclude that the phenotypes observed in our model is most likely due to the effects specifically observed in the hepatocytes. This information has been included in the Results (subsection "PPARα Is Required for Protection against Neonatal Hepatic Steatosis", second paragraph)

*2) The hepatic steatosis in Ppara^-/-^is caused by? The dietary fat or more related to the carb part of the diet leading to de novo lipogenesis that is also under control of PPARα, I thought (references are not mentioned describing the role in regulating \'new\' fat metabolism). Translated to the human situation early breastmilk has a rather low fat content and as a baby breastfeeds, the fat content very gradually increases, with the milk becoming fattier and fattier over time. So in the beginning is largely a sweet high lactose/carb feed; how does this relate to this study?*

We thank the reviewer for highlighting these important points. In our opinion, it is the deficiency in metabolising the dietary fat that contributes to this steatotic phenotype in *Ppara^-/-^* livers because in the early days of life mouse milk is abundant in lipids and insulin level is low while glucagon is high, which promotes FAO rather than de novo synthesis of FA (Girard et al., 1977) (doi: 10.1007/978-1-4612-6366-1_36). As discovered by Semenkovich and co-workers (Chakravarthy et al., 2005, Chakravarthy et al., 2009) (PMID:16054078, 19646743), new FA synthesized by fatty acid synthase regulates glucose, lipid, and cholesterol metabolism by serving as endogenous activators of distinct physiological pools of PPARα in adult liver. However, we doubt that de novo synthesis of FA plays a predominant role in the regulation of PPARα activity during early postnatal period since insulin/glucagon ratio is low.

We agree with the reviewer that early human breast milk has a rather relatively low fat content (3%-5%) and a relatively high content of lactose/carbohydrate (6.9%-7.2%). As described by Jenness (1979) (PMID: 392766), fat content does not vary much during lactation but exhibits large diurnal variations and increases during the course of each nursing. Therefore, the human breast milk may be classified as not ketogenic. However, both newborn humans and mouse pups are in ketogenic conditions, in which similar plasma concentrations of ketone body were detected in both species (0.2-0.5 mmol/L) (Hamosh, 2004) (doi:10.1016/B978-0-7216-9654-6.50032-1). This neonatal ketogenic condition could be due to a low plasma insulin/glucagon ratio at this stage of life. Furthermore, many scientists are more inclined towards the notion that lactose and oligosaccharides−two of the main carbohydrates present in the milk, are not used as general fuel, but preferentially to support the growth of the brain and myelin synthesis as well as to provide nutrients for the newly established gut microbiota of infants (Edmond, 1992; Chichlowski et al., 2011) (PMID: 1295662, 22129386). Indeed, many believe that the reason for such a ketogenic environment in human infants is crucial to preserve carbohydrates for the development of the brain (Klepper et al., 2002) (PMID: 12555938). Therefore, oxidative metabolism of lipids represents a preferred fuel for the newborns. We have tried to clarify and discussed this important information in the Discussion (sixth paragraph).

*3) Related to this the HF diets used for the challenge are quite extreme, ketogenic diets, why this is needed as I guess this is not the same in the human situation? I do not see the full relevance for this challenge? To induce FGF21? Is FGF21 functional for early nutrition related metabolic regulation or more related to starvation/low calorie periods of the baby (where β-hydroxybutyrate also goes up?), so is it ketogenesis because of ketogenic diets or fasting-related metabolic states? I am not really convinced of the diets used here to mimic (human) milk. Human milk is clearly not a ketogenic diet. So I question the regulation of FGF21 because of the milk.*

We thank the reviewer for bringing to our attention this lack of clarity. Relating to the previous comment, the purpose of the high-fat diet (HFD) challenge we performed in this experiment was to test whether the change in food composition that occurs at weaning is responsible for the reduction in the fatty liver phenotype as observed in *Ppara^-/-^* pups after P5-6 ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Indeed, many other changes occur at weaning, including changes in the insulin/glucagon ratio (Girard et al., 1977). The high-fat diet (HFD) experiment indicates that the lipid content of the milk primarily contributes to the development of liver steatosis in *Ppara^-/-^* pups. Our findings suggest that the concomitant presence of mitochondrial dysfunction (cum defective oxidative capacity) and dietary fat synergistically contribute to the development of liver steatosis in *Ppara^-/-^* neonates. As discussed in our response to comment \#2, both newborn humans and mouse pups are in ketogenic condition (Medina and Tabernero, 2005) (PMID: 15573408). We believe that the high circulating levels of ketone bodies (e.g., β-hydroxybutyrate) in neonates are due to the use of lipids as the preferred fuel to support the energy demand for growth. This in turn induces FGF21 through HDAC3 inhibition by ketone bodies. We believe that the induction of FGF21 in neonates after milk suckling relates more to metabolic regulation rather than a response to starvation/low calorie condition which should no longer exist upon milk ingestion. This notion is substantiated by the stimulatory effects of FGF21 on hepatic FAO and energy expenditure to prevent hepatic steatosis following milk ingestion (Xu et al., 2009) (PMID: PMC2606881). We have clarified this point in the Results (subsection "PPARα Is Required for Protection against Neonatal Hepatic Steatosis", second paragraph). We have also discussed this important point in the Discussion (sixth paragraph).

*4) The composition is not precisely mentioned e.g. no lactose or sucrose in the diet?). On the other hand, using chow is not ideal as it will prevent the exact reproducibility of this study because of the natural/variable ingredients of the chow.*

We have provided the formulation for all the diets used in this study ([Tables 1](#tbl1){ref-type="table"}, [4](#tbl4){ref-type="table"}, [5](#tbl5){ref-type="table"}). We used an internationally recognised formulation, AIN93M, which specifies the total energy derived from carbohydrate, fat, and protein to be 76%, 9%, and 15%, respectively. Although the ingredients used for each chow diet may vary to suit locally available raw materials, the formulation and the% total energy guideline should allow reproducibility of this study.

*In summary, I am not so convinced yet that the main finding of this paper (epigenetic regulation of FGF21, which has been partly described before, and partly attributed to SIRT1/3) is really related to the HF diet challenge but it could be also alternatively explained as it might contribute in the difficult periods of low-/no-food /starvation when bHB is providing fuel for the brain to optimize glucose transport by other organs to prevent hypoglycemia etc.?*

We thank the reviewer for highlighting this important point. We have discussed the work by Marrero and co-workers (Vilà-Brau et al., 2011) (PMID: 2150232) in which they show that FGF21 is specifically induced by HMGCS2 activity and that the oxidized form of ketone bodies (acetoacetate) could also induce FGF21, possibly via a SIRT1-dependent mechanism.However, as discussed in comments \#2 and \#3, the induction of FGF21 is likely linked to the ketogenic condition in neonates. It is unclear why neonates exhibit higher circulating levels of ketone bodies. We believe that it could be associated with the use of lipids as preferred fuel for growth while the carbohydrate parts of milk contribute to brain growth and gut microbiota nourishment. Further, the ketogenic condition may also be explained by the low insulin/glucagon ratio in early postpartum life. Regardless, it is clear that ketone bodies act as a hit that is important to prime PPARα-dependent expression of *Fgf21* by modulating HDAC3 activity on *Fgf21* promoter. As suggested by the reviewer, we have tried to further discuss and clarify this important information in the Discussion (fifth and sixth paragraphs).

[^1]: These authors contributed equally to this work.

[^2]: Calculated data uses information from typical raw material composition. It could be expected that individual batches of diet will vary from this figure. Diet post treatment by irradiation or autoclave could change these parameters. We are happy to provide full calculated nutritional information for all of our products, however we would like to emphasise that these diets have been specifically designed for manufacture by Specialty Feeds.
